Contract Research Organization (CRO) Services Market by Type (Early Phase, Clinical, Lab, Consulting), Therapeutic Area [Oncology (Breast, Lung), Infectious, Neurology, Vaccines], Modality, Model (FSO, FSP), End User, Competition - Global Forecast to 2031

1 INTRODUCTION 57 1.1 STUDY OBJECTIVES 57 1.2 MARKET DEFINITION 57 1.3 STUDY SCOPE 58 1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE 58 1.3.2 INCLUSIONS AND EXCLUSIONS 59 1.3.3 YEARS CONSIDERED 60 1.3.4 CURRENCY CONSIDERED 61 1.4 STAKEHOLDERS 61 1.5 SUMMARY OF CHANGES 61 2 EXECUTIVE SUMMARY 63 2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS 63 2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS 64 2.3 DISRUPTIVE TRENDS SHAPING THE MARKET 65 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 66 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 67 3 PREMIUM INSIGHTS 69 3.1 GLOBAL CRO SERVICES MARKET SNAPSHOT 69 3.2 NORTH AMERICA: CRO SERVICES MARKET, BY MODALITY AND COUNTRY, 2024 70 3.3 CRO SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 71 4 MARKET OVERVIEW 72 4.1 INTRODUCTION 72 4.2 MARKET DYNAMICS 72 4.2.1 DRIVERS 73 4.2.1.1 Rising trial volume and complexity 73 4.2.1.2 Growing focus on decentralized/patient-centric trials 74 4.2.1.3 Service flexibility offered by CROs 74 4.2.1.4 Technological integrations 75 4.2.1.5 Growing R&D investments and presence of a robust clinical pipeline 76 4.2.2 OPPORTUNITIES 77 4.2.2.1 Growing regulatory stringency on the diversity of the patient pool 77 4.2.2.2 Risk-based monitoring (RBM) and risk-based quality management as a service 77 4.2.2.3 Offering data analysis outcomes favoring clients’ reimbursement and market access strategy 78 4.2.2.4 AI-powered clinical development and decentralized trial models 78   4.2.3 CHALLENGES 79 4.2.3.1 Patient retention 79 4.2.3.2 Cybersecurity or intellectual property challenges 79 4.3 UNMET NEEDS AND WHITE SPACES 79 4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES 80 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 80 5 INDUSTRY TRENDS 81 5.1 MARKET TRENDS 81 5.1.1 INTEGRATION OF HEOR AND RWE INTO CLINICAL TRIAL DESIGN 81 5.1.2 IN SILICO TRIALS 81 5.1.3 SPECIALIZED BIOANALYTICS FOR EMERGING MODALITIES (CGT) 82 5.2 PORTER’S FIVE FORCES ANALYSIS 83 5.2.1 THREAT OF NEW ENTRANTS 84 5.2.2 THREAT OF SUBSTITUTES 84 5.2.3 BARGAINING POWER OF BUYERS 84 5.2.4 BARGAINING POWER OF SUPPLIERS 84 5.2.5 INTENSITY OF COMPETITIVE RIVALRY 84 5.3 MACROECONOMIC OUTLOOK 85 5.3.1 INTRODUCTION 85 5.3.2 GDP TRENDS AND FORECAST 85 5.3.3 TRENDS IN GLOBAL CRO SERVICES MARKET 85 5.4 VALUE CHAIN ANALYSIS 86 5.5 ECOSYSTEM ANALYSIS 87 5.6 PRICING ANALYSIS 89 5.6.1 INDICATIVE PRICING RANGE, BY SERVICE TYPE, 2025 89 5.6.2 INDICATIVE PRICING ANALYSIS, BY PHASE, 2025 90 5.6.3 INDICATIVE PRICING ANALYSIS, BY REGION, 2025 90 5.7 KEY CONFERENCES & EVENTS, 2026–2027 91 5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 92 5.9 INVESTMENT AND FUNDING SCENARIO 92 5.10 IMPACT OF 2025 US TARIFFS—CRO SERVICES MARKET 93 5.10.1 INTRODUCTION 93 5.10.2 KEY TARIFF RATES 93 5.10.3 PRICE IMPACT ANALYSIS 93 5.10.4 IMPACT ON COUNTRIES/REGIONS 94 5.10.4.1 North America 94 5.10.4.1.1 US 94 5.10.4.2 Europe 94 5.10.4.3 Asia Pacific 95 5.10.5 IMPACT ON END-USE INDUSTRIES 95 5.10.5.1 Pharmaceutical & biotech companies 95 5.10.5.2 Medical device companies 96 5.10.5.3 Academic institutes 96 6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, INNOVATIONS, AND FUTURE APPLICATIONS 97 6.1 KEY TECHNOLOGIES 97 6.1.1 AI-INTEGRATED CLINICAL TRIAL MANAGEMENT SYSTEM (CTMS) & ELECTRONIC TRIAL MASTER FILE (ETMF) PLATFORMS 97 6.1.2 RANDOMIZATION AND TRIAL SUPPLY MANAGEMENT (RTSM) 97 6.1.3 ELECTRONIC DATA CAPTURE (EDC) SYSTEM 98 6.2 COMPLEMENTARY TECHNOLOGIES 98 6.2.1 DIGITAL BIOMARKERS, WEARABLES & ELECTRONIC PATIENT-REPORTED OUTCOME (EPRO) TOOLS 98 6.2.2 MODEL-INFORMED DRUG DEVELOPMENT (MIDD) 99 6.2.3 DATA MANAGEMENT AND INFORMATICS TECHNOLOGIES 99 6.2.4 REAL-WORLD EVIDENCE (RWE) & REAL-WORLD DATA (RWD) PLATFORMS 100 6.3 ADJACENT TECHNOLOGIES 100 6.3.1 CLINICAL TRIAL SIMULATION TOOLS 100 6.4 TECHNOLOGY/SERVICE ROADMAP 100 6.5 FUTURE APPLICATIONS 101 6.6 IMPACT OF AI/GEN AI ON CRO SERVICES MARKET 101 6.6.1 INTRODUCTION 101 6.6.2 MARKET POTENTIAL ACROSS DRUG DEVELOPMENT STAGES 101 6.6.3 AI USE CASES 102 6.6.4 FUTURE OF GENERATIVE AI IN DRUG DEVELOPMENT ECOSYSTEM 103 7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES 104 7.1 REGIONAL REGULATIONS AND COMPLIANCE 104 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 104 7.1.2 INDUSTRY STANDARDS 106 7.1.2.1 North America 106 7.1.2.2 Europe 108 7.1.2.3 Asia Pacific 108 7.1.2.4 Rest of the World 109 7.1.3 CERTIFICATIONS, LABELING, & ECO-STANDARDS 110 7.1.4 REGULATORY ANALYSIS 111 7.1.5 REGULATORY SCENARIO FOR DRUG APPROVALS AND CGMP PROCEDURES 111 7.2 SUSTAINABILITY INITIATIVES 114   8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 115 8.1 DECISION-MAKING PROCESS 115 8.2 KEY STAKEHOLDERS INVOLVED IN BUYING PROCESS AND THEIR EVALUATION CRITERIA 115 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 115 8.2.2 BUYING CRITERIA 116 8.3 CUSTOMER LANDSCAPE 117 8.3.1 BUDGET ALLOCATION TREND 117 8.3.2 ADOPTION BARRIERS & INTERNAL CHALLENGES 118 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 118 8.5 MARKET PROFITABILITY 119 9 CRO SERVICES MARKET, BY TYPE 120 9.1 INTRODUCTION 121 9.2 CLINICAL RESEARCH SERVICES 121 9.2.1 PHASE III 126 9.2.1.1 Large-scale testing ability to assess efficacy and safety of drugs to aid growth 126 9.2.2 PHASE II 129 9.2.2.1 Growing number of pipeline products in Phase II studies to drive market 129 9.2.3 PHASE I 133 9.2.3.1 Robust pipeline of pharmaceutical and biopharmaceutical products to support growth 133 9.2.4 PHASE IV 136 9.2.4.1 Stringent global regulations for drug safety monitoring to spur growth 136 9.3 EARLY-PHASE DEVELOPMENT SERVICES 138 9.3.1 CHEMISTRY, MANUFACTURING, AND CONTROLS SERVICES 141 9.3.1.1 Growing need to meet regulatory norms for drugs to fuel market 141 9.3.2 PRECLINICAL SERVICES 144 9.3.2.1 Pharmacokinetics/Pharmacodynamics 147 9.3.2.1.1 Rise in outsourcing services by pharmaceutical and biopharmaceutical companies to promote growth 147 9.3.2.2 Toxicology testing 150 9.3.2.2.1 Need to prevent late-stage failures to contribute to growth 150 9.3.2.3 Other preclinical services 153 9.3.3 DISCOVERY STUDIES 156 9.3.3.1 Increasing reliance on CRO services for target identification and validation to expedite growth 156 9.4 LABORATORY SERVICES 159 9.4.1 ANALYTICAL TESTING 162 9.4.1.1 Physical characterization 165 9.4.1.1.1 Ability to minimize product failure in late-phase development to favor growth 165 9.4.1.2 Raw material testing 168 9.4.1.2.1 Need to maintain quality of finished product to facilitate growth 168 9.4.1.3 Batch-release testing 172 9.4.1.3.1 Need to maintain batch-to-batch consistency of pharmaceutical dosage forms to advance growth 172 9.4.1.4 Stability testing 174 9.4.1.4.1 Ability to establish drug compatibility and formulation development to aid growth 174 9.4.1.5 Other analytical testing services 178 9.4.2 BIOANALYTICAL TESTING 180 9.4.2.1 Increasing outsourcing of R&D activities to accelerate growth 180 9.5 CONSULTING SERVICES 184 9.5.1 GROWING ADOPTION OF CONSULTING SERVICES FOR FASTER REGULATORY APPROVALS TO BOOST MARKET 184 9.6 DATA MANAGEMENT SERVICES 187 9.6.1 NEED TO TRACK PROGRESS OF EARLY DRUG DEVELOPMENT TO AUGMENT GROWTH 187 10 CRO SERVICES MARKET, BY DELIVERY MODEL 191 10.1 INTRODUCTION 192 10.2 FULL-SERVICE OUTSOURCING (FSO) MODEL 192 10.2.1 RISE IN NUMBER OF EMERGING BIOPHARMACEUTICAL COMPANIES TO DRIVE MARKET 192 10.3 FUNCTIONAL SERVICE PROVIDER (FSP) MODEL 195 10.3.1 GROWING ADOPTION OF FSP SERVICES BY LARGE PHARMACEUTICAL COMPANIES TO FUEL MARKET GROWTH 195 10.4 HYBRID MODEL 198 10.4.1 HIGH FLEXIBILITY OFFERED BY HYBRID MODEL TO SUPPORT MARKET GROWTH 198 11 CRO SERVICES MARKET, BY MODALITY 201 11.1 INTRODUCTION 202 11.2 SMALL MOLECULES 202 11.2.1 ONGOING SURGE IN PHARMACEUTICAL R&D INVESTMENTS TO SUPPORT GROWTH 202 11.3 BIOLOGICS 205 11.3.1 MONOCLONAL ANTIBODIES 209 11.3.1.1 Surging demand for targeted therapies across oncology, autoimmune disorders, and infectious diseases to drive market 209 11.3.2 CELL & GENE THERAPY 212 11.3.2.1 Robust pipeline and R&D initiatives to drive market 212 11.3.3 OTHER BIOLOGICS 216   11.4 MEDICAL DEVICES 219 11.4.1 RAPID INNOVATIONS IN DIAGNOSTICS, IMPLANTABLES, AND DIGITAL HEALTH TECHNOLOGIES TO FOSTER GROWTH 219 11.5 BIOSIMILARS 221 11.5.1 MONOCLONAL ANTIBODY BIOSIMILARS 225 11.5.1.1 Rising demand for affordable therapeutic options to support growth 225 11.5.2 INSULIN 228 11.5.2.1 Increasing patent expirations to contribute to growth 228 11.5.3 COLONY-STIMULATING FACTORS 231 11.5.3.1 Increasing use of colony-stimulating factor during post-chemotherapy to aid growth 231 11.5.4 ERYTHROPOIETIN 234 11.5.4.1 Essential role of erythropoietin in treating anemia to stimulate growth 234 11.5.5 OTHER BIOSIMILARS 237 12 CRO SERVICES MARKET, BY THERAPEUTIC AREA 240 12.1 INTRODUCTION 241 12.2 ONCOLOGY 242 12.2.1 GROWING INCIDENCE OF CANCER TO DRIVE MARKET 242 12.2.2 BREAST CANCER 246 12.2.2.1 Increasing cases and high spending on treating breast cancer to support growth 246 12.2.3 LUNG CANCER 249 12.2.3.1 Increasing focus on developing drugs against lung cancer to foster growth 249 12.2.4 COLORECTAL CANCER 252 12.2.4.1 Increasing drug discovery and development efforts against colorectal cancer to aid growth 252 12.2.5 PROSTATE CANCER 254 12.2.5.1 Growing clinical pipeline to propel market 254 12.2.6 OTHER CANCERS 257 12.3 INFECTIOUS DISEASES 260 12.3.1 INCREASING INCIDENCE OF CHRONIC INFECTIONS TO SUPPORT GROWTH 260 12.4 CARDIOVASCULAR SYSTEM DISORDERS 263 12.4.1 HIGH MORTALITY RATES OF CARDIOVASCULAR DISEASES TO FUEL MARKET 263 12.5 NEUROLOGY 266 12.5.1 GROWING INVESTMENTS IN NEUROLOGICAL DISORDER RESEARCH TO DRIVE MARKET 266 12.6 VACCINES 269 12.6.1 INCREASING FOCUS ON VACCINE DEVELOPMENT TO SPUR GROWTH 269 12.7 METABOLIC DISORDERS/ENDOCRINOLOGY 272 12.7.1 INCREASING GLOBAL DIABETES AND OBESITY POPULATION TO PROMOTE GROWTH 272 12.8 IMMUNOLOGICAL DISORDERS 276 12.8.1 GROWING CLINICAL RESEARCH FOR IMMUNOLOGICAL DISORDERS TO BOOST MARKET 276 12.9 PSYCHIATRY 279 12.9.1 RISING CASES OF PSYCHIATRIC DISORDERS AND DEPRESSION TO SUSTAIN GROWTH 279 12.10 RESPIRATORY DISORDERS 282 12.10.1 RISING INCIDENCE OF CHRONIC RESPIRATORY DISEASE TO FOSTER GROWTH 282 12.11 DERMATOLOGY 285 12.11.1 GROWING FOCUS ON DRUG DEVELOPMENT AGAINST VARIOUS SKIN CONDITIONS TO DRIVE MARKET 285 12.12 OPHTHALMOLOGY 288 12.12.1 GROWTH IN NUMBER OF OPHTHALMOLOGY PIPELINE DRUGS TO SUPPORT SEGMENT GROWTH 288 12.13 GASTROINTESTINAL DISEASES 290 12.13.1 RAPID LIFESTYLE AND DIETARY CHANGES TO AMPLIFY GROWTH 290 12.14 GENITOURINARY & WOMEN’S HEALTH 294 12.14.1 RISING AWARENESS ABOUT EARLY DISEASE DIAGNOSIS AND TREATMENT TO BOLSTER MARKET 294 12.15 HEMATOLOGY 296 12.15.1 INCREASING DRUG APPROVALS FOR DRUGS AGAINST NON-MALIGNANT HEMATOLOGICAL CONDITIONS TO SUPPORT GROWTH 296 12.16 OTHER THERAPEUTIC AREAS 299 13 CRO SERVICES MARKET, BY END USER 303 13.1 INTRODUCTION 304 13.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 304 13.2.1 INCREASING OUTSOURCING AND PARTNERSHIPS TO ACCELERATE GROWTH 304 13.2.2 LARGE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 308 13.2.2.1 Demand for therapeutic expertise and global reach to aid outsourcing to CROs 308 13.2.3 SMALL & MID-SIZE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 311 13.2.3.1 Demand is driven by need to control fixed costs, access global development expertise, and accelerate timelines 311 13.3 MEDICAL DEVICE COMPANIES 314 13.3.1 INCREASING GROWTH INITIATIVES BY MEDTECH CROS TO DRIVE MARKET 314 13.4 ACADEMIC INSTITUTES 318 13.4.1 CONSISTENT COLLABORATIONS BETWEEN CROS AND ACADEMIA TO INTENSIFY GROWTH 318 14 CRO SERVICES MARKET, BY REGION 322 14.1 INTRODUCTION 323 14.2 NORTH AMERICA 323 14.2.1 US 330 14.2.1.1 Increasing incidence of oncology indications to accelerate growth 330 14.2.2 CANADA 337 14.2.2.1 Favorable government initiatives and high investments to support growth 337 14.3 EUROPE 343 14.3.1 GERMANY 349 14.3.1.1 Presence of strong pharmaceutical and biotechnology R&D infrastructure to spur growth 349 14.3.2 UK 355 14.3.2.1 Rising pharmaceutical R&D expenditure to expedite growth 355 14.3.3 FRANCE 360 14.3.3.1 Increasing technological advancements and faster drug discovery and development initiatives to aid growth 360 14.3.4 ITALY 366 14.3.4.1 Short timeline for drug approvals to encourage growth 366 14.3.5 SPAIN 372 14.3.5.1 Growing investment in pharmaceutical industry to boost market 372 14.3.6 REST OF EUROPE 377 14.4 ASIA PACIFIC 383 14.4.1 CHINA 389 14.4.1.1 Continued efforts on improving the level of drug safety and supply to spur growth 389 14.4.2 INDIA 395 14.4.2.1 Large pool of patients and presence of highly skilled medical professionals to augment growth 395 14.4.3 JAPAN 401 14.4.3.1 Growing drug development activity to propel market 401 14.4.4 AUSTRALIA 407 14.4.4.1 Growing focus on funding opportunities to propel market 407 14.4.5 SOUTH KOREA 413 14.4.5.1 Emerging clinical research hub to sustain growth 413 14.4.6 REST OF ASIA PACIFIC 419 14.5 LATIN AMERICA 425 14.5.1 BRAZIL 431 14.5.1.1 Growing focus on enhancing pharmaceutical research and production to fuel market 431 14.5.2 MEXICO 436 14.5.2.1 Increasing investments in pharma R&D to promote growth 436 14.5.3 REST OF LATIN AMERICA 442 14.6 MIDDLE EAST 447 14.6.1 GCC COUNTRIES 452 14.6.1.1 Kingdom of Saudi Arabia (KSA) 458 14.6.1.1.1 Expanding clinical trials ecosystem to contribute to growth 458 14.6.1.2 United Arab Emirates (UAE) 464 14.6.1.2.1 Growing clinical trials activity to drive market 464 14.6.1.3 Rest of GCC Countries 470 14.6.2 REST OF MIDDLE EAST 475 14.7 AFRICA 481 14.7.1 BOOMING PHARMACEUTICAL INDUSTRY TO FACILITATE GROWTH 481 15 COMPETITIVE LANDSCAPE 487 15.1 INTRODUCTION 487 15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 487 15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CRO SERVICES MARKET, JANUARY 2023-MARCH 2026 487 15.3 REVENUE ANALYSIS, 2021–2025 489 15.4 MARKET SHARE ANALYSIS, 2025 489 15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 492 15.5.1 STARS 492 15.5.2 EMERGING LEADERS 492 15.5.3 PERVASIVE PLAYERS 492 15.5.4 PARTICIPANTS 492 15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 494 15.5.5.1 Company footprint 494 15.5.5.2 Region footprint 495 15.5.5.3 Type footprint 496 15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 497 15.6.1 PROGRESSIVE COMPANIES 497 15.6.2 RESPONSIVE COMPANIES 497 15.6.3 DYNAMIC COMPANIES 497 15.6.4 STARTING BLOCKS 497 15.6.5 COMPETITIVE BENCHMARKING 499 15.6.5.1 Detailed list of key startups/SMEs 499 15.6.5.2 Competitive benchmarking of startups/SMEs 500 15.7 COMPANY VALUATION & FINANCIAL METRICS 501 15.7.1 FINANCIAL METRICS 501 15.7.2 COMPANY VALUATION 501 15.8 SERVICE COMPARISON 502 15.9 COMPETITIVE SCENARIO 503 15.9.1 SERVICE LAUNCHES & APPROVALS 503 15.9.2 DEALS 504 15.9.3 EXPANSIONS 505   16 COMPANY PROFILES 506 16.1 KEY PLAYERS 506 16.1.1 IQVIA INC. 506 16.1.1.1 Business overview 506 16.1.1.2 Services/Solutions offered 507 16.1.1.3 Recent developments 509 16.1.1.3.1 Product & service launches 509 16.1.1.3.2 Deals 510 16.1.1.4 MnM view 511 16.1.1.4.1 Key strengths/Right to win 511 16.1.1.4.2 Strategic choices made 512 16.1.1.4.3 Weaknesses and competitive threats 512 16.1.2 ICON PLC 513 16.1.2.1 Business overview 513 16.1.2.2 Services/Solutions offered 514 16.1.2.3 Recent developments 516 16.1.2.3.1 Service launches 516 16.1.2.3.2 Deals 516 16.1.2.3.3 Expansions 517 16.1.2.4 MnM view 517 16.1.2.4.1 Key strengths/Right to win 517 16.1.2.4.2 Strategic choices made 517 16.1.2.4.3 Weaknesses and competitive threats 517 16.1.3 THERMO FISHER SCIENTIFIC INC. 518 16.1.3.1 Business overview 518 16.1.3.2 Services/Solutions offered 519 16.1.3.3 Recent developments 521 16.1.3.3.1 Service launches 521 16.1.3.3.2 Deals 522 16.1.3.3.3 Expansions 523 16.1.3.4 MnM view 523 16.1.3.4.1 Key strengths/Right to win 523 16.1.3.4.2 Strategic choices made 524 16.1.3.4.3 Weaknesses and competitive threats 524 16.1.4 LABORATORY CORPORATION OF AMERICA HOLDINGS 525 16.1.4.1 Business overview 525 16.1.4.2 Services/Solutions offered 526 16.1.4.3 Recent developments 528 16.1.4.3.1 Service launches 528 16.1.4.3.2 Deals 528 16.1.4.3.3 Expansions 529 16.1.4.3.4 Other developments 530 16.1.4.4 MnM view 530 16.1.4.4.1 Key strengths/Right to win 530 16.1.4.4.2 Strategic choices made 530 16.1.4.4.3 Weaknesses and competitive threats 530 16.1.5 FORTREA, INC. 531 16.1.5.1 Company overview 531 16.1.5.2 Services/Solutions offered 532 16.1.5.3 Recent developments 534 16.1.5.3.1 Service launches 534 16.1.5.3.2 Deals 535 16.1.5.3.3 Expansions 536 16.1.5.3.4 Other developments 536 16.1.5.4 MnM view 536 16.1.5.4.1 Key strengths/Right to win 536 16.1.5.4.2 Strategic choices made 536 16.1.5.4.3 Weaknesses and competitive threats 536 16.1.6 SYNEOS HEALTH 537 16.1.6.1 Business overview 537 16.1.6.2 Services/Solutions offered 537 16.1.6.3 Recent developments 539 16.1.6.3.1 Service launches 539 16.1.6.3.2 Deals 539 16.1.7 WUXI APPTEC 541 16.1.7.1 Business overview 541 16.1.7.2 Services/Solutions offered 542 16.1.7.3 Recent developments 544 16.1.7.3.1 Expansions 544 16.1.7.3.2 Other developments 545 16.1.8 CHARLES RIVER LABORATORIES 546 16.1.8.1 Business overview 546 16.1.8.2 Services/Solutions offered 547 16.1.8.3 Recent developments 548 16.1.8.3.1 Deals 548 16.1.9 PAREXEL INTERNATIONAL CORPORATION 550 16.1.9.1 Business overview 550 16.1.9.2 Services/Solutions offered 551 16.1.9.3 Recent developments 552 16.1.9.3.1 Deals 552 16.1.9.3.2 Expansions 553 16.1.10 PHARMARON 554 16.1.10.1 Business overview 554 16.1.10.2 Services/Solutions offered 555 16.1.11 MEDPACE 557 16.1.11.1 Business overview 557 16.1.11.2 Services/Solutions offered 558 16.1.12 SGS SA 560 16.1.12.1 Business overview 560 16.1.12.2 Services/Solutions offered 561 16.1.12.3 Recent developments 563 16.1.12.3.1 Deals 563 16.1.13 FRONTAGE LABS 564 16.1.13.1 Business overview 564 16.1.13.2 Services/Solutions offered 565 16.1.13.3 Recent developments 567 16.1.13.3.1 Deals 567 16.1.13.3.2 Other developments 568 16.1.14 EUROFINS SCIENTIFIC 569 16.1.14.1 Business overview 569 16.1.14.2 Services/Solutions offered 570 16.1.15 TIGERMED 572 16.1.15.1 Business overview 572 16.1.15.2 Services offered 573 16.1.15.3 Recent developments 575 16.1.15.3.1 Product/Service approvals 575 16.1.15.3.2 Deals 575 16.1.16 PSI CRO AG 577 16.1.16.1 Business overview 577 16.1.16.2 Services/Solutions offered 577 16.1.16.3 Recent developments 578 16.1.16.3.1 Service launches 578 16.1.16.3.2 Deals 578 16.1.16.3.3 Expansions 579 16.1.17 BIOAGILE 580 16.1.17.1 Business overview 580 16.1.17.2 Services/Solutions offered 580 16.1.18 FIRMA CLINICAL RESEARCH 582 16.1.18.1 Business overview 582 16.1.18.2 Services/Solutions offered 582 16.1.19 ACCULAB LIFE SCIENCES 583 16.1.19.1 Business overview 583 16.1.19.2 Services/Solutions offered 583 16.1.20 NOVOTECH 584 16.1.20.1 Business overview 584 16.1.20.2 Services/Solutions offered 584 16.1.20.3 Recent developments 586 16.1.20.3.1 Deals 586 16.1.21 LINICAL 588 16.1.21.1 Business overview 588 16.1.21.2 Services/Solutions offered 588 16.1.21.3 Recent developments 589 16.1.21.3.1 Expansions 589 16.1.22 ADVANCED CLINICAL 590 16.1.22.1 Business overview 590 16.1.22.2 Services/Solutions offered 590 16.1.22.3 Recent developments 591 16.1.22.3.1 Deals 591 16.2 OTHER PLAYERS 592 16.2.1 ALLUCENT 592 16.2.2 EMVENIO 593 16.2.3 GUIRES INC. (PEPGRA HEALTHCARE PVT. LTD.) 594 16.2.4 WORLDWIDE CLINICAL TRIALS 595 16.2.5 CTI CLINICAL TRIAL & CONSULTING 596 17 RESEARCH METHODOLOGY 598 17.1 RESEARCH APPROACH 598 17.1.1 SECONDARY DATA 599 17.1.1.1 Key sources of secondary data 599 17.1.1.2 Key objectives of secondary research 599 17.1.2 PRIMARY DATA 600 17.1.2.1 Breakdown of primaries 600 17.1.2.2 Key objectives of primary research 600 17.2 MARKET ESTIMATION METHODOLOGY 601 17.2.1 COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH) 601 17.2.2 MNM REPOSITORY ANALYSIS AND PRIMARY RESEARCH 603 17.2.3 SEGMENTAL MARKET ASSESSMENT (TOP-DOWN APPROACH) 604 17.3 GROWTH RATE PROJECTIONS 606 17.4 DATA TRIANGULATION 608 17.5 RESEARCH ASSUMPTIONS 609 17.6 RESEARCH LIMITATIONS 610 17.7 RISK ANALYSIS 610   18 APPENDIX 611 18.1 DISCUSSION GUIDE 611 18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 616 18.3 CUSTOMIZATION OPTIONS 618 18.4 RELATED REPORTS 619 18.5 AUTHOR DETAILS 620

TABLE 1 IMPACT ANALYSIS: CRO SERVICES MARKET 73 TABLE 2 PORTER’S FIVE FORCES ANALYSIS: CRO SERVICES MARKET 83 TABLE 3 CRO SERVICES MARKET: ROLE OF COMPANIES IN ECOSYSTEM 88 TABLE 4 INDICATIVE PRICING RANGE, BY SERVICE TYPE, 2025 (USD) 89 TABLE 5 INDICATIVE PRICING ANALYSIS, BY SERVICE TYPE, 2025 (USD MILLION) 90 TABLE 6 INDICATIVE PRICING ANALYSIS (PER STUDY), BY REGION, 2025 (USD MILLION) 90 TABLE 7 DETAILED LIST OF KEY CONFERENCES & EVENTS, 2026–2027 91 TABLE 8 BEST PRACTICES FOLLOWED BY COMPANIES IN CRO SERVICES MARKET 103 TABLE 9 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 104 TABLE 10 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 105 TABLE 11 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 105 TABLE 12 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 106 TABLE 13 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CRO SERVICES, BY MODALITY 116 TABLE 14 BUYING CRITERIA FOR CRO SERVICES ACROSS END USERS 116 TABLE 15 CRO SERVICES: ADOPTION BARRIERS & INTERNAL FRICTION 118 TABLE 16 CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 121 TABLE 17 CLINICAL RESEARCH SERVICES OFFERED BY MARKET PLAYERS 122 TABLE 18 CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2024–2031 (USD MILLION) 123 TABLE 19 CLINICAL RESEARCH SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 124 TABLE 20 NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 124 TABLE 21 EUROPE: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 124 TABLE 22 ASIA PACIFIC: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 125 TABLE 23 LATIN AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 125 TABLE 24 MIDDLE EAST: CLINICAL RESEARCH SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 125 TABLE 25 GCC COUNTRIES: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 126 TABLE 26 CLINICAL RESEARCH SERVICES MARKET FOR PHASE III, BY REGION, 2024–2031 (USD MILLION) 127 TABLE 27 NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET FOR PHASE III, BY COUNTRY, 2024–2031 (USD MILLION) 127 TABLE 28 EUROPE: CLINICAL RESEARCH SERVICES MARKET FOR PHASE III, BY COUNTRY, 2024–2031 (USD MILLION) 128 TABLE 29 ASIA PACIFIC: CLINICAL RESEARCH SERVICES MARKET FOR PHASE III, BY COUNTRY, 2024–2031 (USD MILLION) 128 TABLE 30 LATIN AMERICA: CLINICAL RESEARCH SERVICES MARKET FOR PHASE III, BY COUNTRY, 2024–2031 (USD MILLION) 129 TABLE 31 MIDDLE EAST: CLINICAL RESEARCH SERVICES MARKET FOR PHASE III, BY REGION, 2024–2031 (USD MILLION) 129 TABLE 32 GCC COUNTRIES: CLINICAL RESEARCH SERVICES MARKET FOR PHASE III, BY COUNTRY, 2024–2031 (USD MILLION) 129 TABLE 33 CLINICAL RESEARCH SERVICES MARKET FOR PHASE II, BY REGION, 2024–2031 (USD MILLION) 130 TABLE 34 NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET FOR PHASE II, BY COUNTRY, 2024–2031 (USD MILLION) 130 TABLE 35 EUROPE: CLINICAL RESEARCH SERVICES MARKET FOR PHASE II, BY COUNTRY, 2024–2031 (USD MILLION) 131 TABLE 36 ASIA PACIFIC: CLINICAL RESEARCH SERVICES MARKET FOR PHASE II, BY COUNTRY, 2024–2031 (USD MILLION) 131 TABLE 37 LATIN AMERICA: CLINICAL RESEARCH SERVICES MARKET FOR PHASE II, BY COUNTRY, 2024–2031 (USD MILLION) 132 TABLE 38 MIDDLE EAST: CLINICAL RESEARCH SERVICES MARKET FOR PHASE II, BY REGION, 2024–2031 (USD MILLION) 132 TABLE 39 GCC COUNTRIES: CLINICAL RESEARCH SERVICES MARKET FOR PHASE II, BY COUNTRY, 2024–2031 (USD MILLION) 132 TABLE 40 CLINICAL RESEARCH SERVICES MARKET FOR PHASE I, BY REGION, 2024–2031 (USD MILLION) 133 TABLE 41 NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET FOR PHASE I, BY COUNTRY, 2024–2031 (USD MILLION) 133 TABLE 42 EUROPE: CLINICAL RESEARCH SERVICES MARKET FOR PHASE I, BY COUNTRY, 2024–2031 (USD MILLION) 134 TABLE 43 ASIA PACIFIC: CLINICAL RESEARCH SERVICES MARKET FOR PHASE I, BY COUNTRY, 2024–2031 (USD MILLION) 134 TABLE 44 LATIN AMERICA: CLINICAL RESEARCH SERVICES MARKET FOR PHASE I, BY COUNTRY, 2024–2031 (USD MILLION) 135 TABLE 45 MIDDLE EAST: CLINICAL RESEARCH SERVICES MARKET FOR PHASE I, BY REGION, 2024–2031 (USD MILLION) 135 TABLE 46 GCC COUNTRIES: CLINICAL RESEARCH SERVICES MARKET FOR PHASE I, BY COUNTRY, 2024–2031 (USD MILLION) 135 TABLE 47 CLINICAL RESEARCH SERVICES MARKET FOR PHASE IV, BY REGION, 2024–2031 (USD MILLION) 136 TABLE 48 NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET FOR PHASE IV, BY COUNTRY, 2024–2031 (USD MILLION) 136 TABLE 49 EUROPE: CLINICAL RESEARCH SERVICES MARKET FOR PHASE IV, BY COUNTRY, 2024–2031 (USD MILLION) 137 TABLE 50 ASIA PACIFIC: CLINICAL RESEARCH SERVICES MARKET FOR PHASE IV, BY COUNTRY, 2024–2031 (USD MILLION) 137 TABLE 51 LATIN AMERICA: CLINICAL RESEARCH SERVICES MARKET FOR PHASE IV, BY COUNTRY, 2024–2031 (USD MILLION) 137 TABLE 52 MIDDLE EAST: CLINICAL RESEARCH SERVICES MARKET FOR PHASE IV, BY REGION, 2024–2031 (USD MILLION) 138 TABLE 53 GCC COUNTRIES: CLINICAL RESEARCH SERVICES MARKET FOR PHASE IV, BY COUNTRY, 2024–2031 (USD MILLION) 138 TABLE 54 EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 139 TABLE 55 EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 139 TABLE 56 NORTH AMERICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 139 TABLE 57 EUROPE: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 140 TABLE 58 ASIA PACIFIC: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 140 TABLE 59 LATIN AMERICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 141 TABLE 60 MIDDLE EAST: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 141 TABLE 61 GCC COUNTRIES: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 141 TABLE 62 CMC SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 142 TABLE 63 NORTH AMERICA: CMC SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 142 TABLE 64 EUROPE: CMC SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 143 TABLE 65 ASIA PACIFIC: CMC SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 143 TABLE 66 LATIN AMERICA: CMC SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 143 TABLE 67 MIDDLE EAST: CMC SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 144 TABLE 68 GCC COUNTRIES: CMC SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 144 TABLE 69 PRECLINICAL SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 145 TABLE 70 PRECLINICAL SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 145 TABLE 71 NORTH AMERICA: PRECLINICAL SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 145 TABLE 72 EUROPE: PRECLINICAL SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 146 TABLE 73 ASIA PACIFIC: PRECLINICAL SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 146 TABLE 74 LATIN AMERICA: PRECLINICAL SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 146 TABLE 75 MIDDLE EAST: PRECLINICAL SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 147 TABLE 76 GCC COUNTRIES: PRECLINICAL SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 147 TABLE 77 PK/PD SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 148 TABLE 78 NORTH AMERICA: PK/PD SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 148 TABLE 79 EUROPE: PK/PD SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 148 TABLE 80 ASIA PACIFIC: PK/PD SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 149 TABLE 81 LATIN AMERICA: PK/PD SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 149 TABLE 82 MIDDLE EAST: PK/PD SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 149 TABLE 83 GCC COUNTRIES: PK/PD SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 150 TABLE 84 TOXICOLOGY TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 151 TABLE 85 NORTH AMERICA: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 151 TABLE 86 EUROPE: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 151 TABLE 87 ASIA PACIFIC: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 152 TABLE 88 LATIN AMERICA: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 152 TABLE 89 MIDDLE EAST: TOXICOLOGY TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 152 TABLE 90 GCC COUNTRIES: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 153 TABLE 91 OTHER PRECLINICAL SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 153 TABLE 92 NORTH AMERICA: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 154 TABLE 93 EUROPE: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 154 TABLE 94 ASIA PACIFIC: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 154 TABLE 95 LATIN AMERICA: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 155 TABLE 96 MIDDLE EAST: OTHER PRECLINICAL SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 155 TABLE 97 GCC COUNTRIES: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 155 TABLE 98 CRO SERVICES MARKET FOR DISCOVERY STUDIES, BY REGION, 2024–2031 (USD MILLION) 156 TABLE 99 NORTH AMERICA: CRO SERVICES MARKET FOR DISCOVERY STUDIES, BY COUNTRY, 2024–2031 (USD MILLION) 156 TABLE 100 EUROPE: CRO SERVICES MARKET FOR DISCOVERY STUDIES, BY COUNTRY, 2024–2031 (USD MILLION) 157 TABLE 101 ASIA PACIFIC: CRO SERVICES MARKET FOR DISCOVERY STUDIES, BY COUNTRY, 2024–2031 (USD MILLION) 157 TABLE 102 LATIN AMERICA: CRO SERVICES MARKET FOR DISCOVERY STUDIES, BY COUNTRY, 2024–2031 (USD MILLION) 158 TABLE 103 MIDDLE EAST: CRO SERVICES MARKET FOR DISCOVERY STUDIES, BY REGION, 2024–2031 (USD MILLION) 158 TABLE 104 GCC COUNTRIES: CRO SERVICES MARKET FOR DISCOVERY STUDIES, BY COUNTRY, 2024–2031 (USD MILLION) 158 TABLE 105 LABORATORY SERVICES OFFERED BY PROMINENT PLAYERS 159 TABLE 106 LABORATORY SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 159 TABLE 107 LABORATORY SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 160 TABLE 108 NORTH AMERICA: LABORATORY SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 160 TABLE 109 EUROPE: LABORATORY SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 160 TABLE 110 ASIA PACIFIC: LABORATORY SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 161 TABLE 111 LATIN AMERICA: LABORATORY SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 161 TABLE 112 MIDDLE EAST: LABORATORY SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 161 TABLE 113 GCC COUNTRIES: LABORATORY SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 162 TABLE 114 ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 162 TABLE 115 ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 163 TABLE 116 NORTH AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 163 TABLE 117 EUROPE: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 163 TABLE 118 ASIA PACIFIC: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 164 TABLE 119 LATIN AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 164 TABLE 120 MIDDLE EAST: ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 164 TABLE 121 GCC COUNTRIES: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 165 TABLE 122 CRO SERVICES MARKET FOR PHYSICAL CHARACTERIZATION, BY REGION, 2024–2031 (USD MILLION) 166 TABLE 123 NORTH AMERICA: CRO SERVICES MARKET FOR PHYSICAL CHARACTERIZATION, BY COUNTRY, 2024–2031 (USD MILLION) 166 TABLE 124 EUROPE: CRO SERVICES MARKET FOR PHYSICAL CHARACTERIZATION, BY COUNTRY, 2024–2031 (USD MILLION) 166 TABLE 125 ASIA PACIFIC: CRO SERVICES MARKET FOR PHYSICAL CHARACTERIZATION, BY COUNTRY, 2024–2031 (USD MILLION) 167 TABLE 126 LATIN AMERICA: CRO SERVICES MARKET FOR PHYSICAL CHARACTERIZATION, BY COUNTRY, 2024–2031 (USD MILLION) 167 TABLE 127 MIDDLE EAST: CRO SERVICES MARKET FOR PHYSICAL CHARACTERIZATION, BY REGION, 2024–2031 (USD MILLION) 167 TABLE 128 GCC COUNTRIES: CRO SERVICES MARKET FOR PHYSICAL CHARACTERIZATION, BY COUNTRY, 2024–2031 (USD MILLION) 168 TABLE 129 CRO SERVICES MARKET FOR RAW MATERIAL TESTING, BY REGION, 2024–2031 (USD MILLION) 169 TABLE 130 NORTH AMERICA: CRO SERVICES MARKET FOR RAW MATERIAL TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 169 TABLE 131 EUROPE: CRO SERVICES MARKET FOR RAW MATERIAL TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 170 TABLE 132 ASIA PACIFIC: CRO SERVICES MARKET FOR RAW MATERIAL TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 170 TABLE 133 LATIN AMERICA: CRO SERVICES MARKET FOR RAW MATERIAL TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 171 TABLE 134 MIDDLE EAST: CRO SERVICES MARKET FOR RAW MATERIAL TESTING, BY REGION, 2024–2031 (USD MILLION) 171 TABLE 135 GCC COUNTRIES: CRO SERVICES MARKET FOR RAW MATERIAL TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 171 TABLE 136 CRO SERVICES MARKET FOR BATCH-RELEASE TESTING, BY REGION, 2024–2031 (USD MILLION) 172 TABLE 137 NORTH AMERICA: CRO SERVICES MARKET FOR BATCH-RELEASE TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 172 TABLE 138 EUROPE: CRO SERVICES MARKET FOR BATCH-RELEASE TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 173 TABLE 139 ASIA PACIFIC: CRO SERVICES MARKET FOR BATCH-RELEASE TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 173 TABLE 140 LATIN AMERICA: CRO SERVICES MARKET FOR BATCH-RELEASE TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 174 TABLE 141 MIDDLE EAST: CRO SERVICES MARKET FOR BATCH-RELEASE TESTING, BY REGION, 2024–2031 (USD MILLION) 174 TABLE 142 GCC COUNTRIES: CRO SERVICES MARKET FOR BATCH-RELEASE TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 174 TABLE 143 CRO SERVICES MARKET FOR STABILITY TESTING, BY REGION, 2024–2031 (USD MILLION) 175 TABLE 144 NORTH AMERICA: CRO SERVICES MARKET FOR STABILITY TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 175 TABLE 145 EUROPE: CRO SERVICES MARKET FOR STABILITY TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 176 TABLE 146 ASIA PACIFIC: CRO SERVICES MARKET FOR STABILITY TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 176 TABLE 147 LATIN AMERICA: CRO SERVICES MARKET FOR STABILITY TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 177 TABLE 148 MIDDLE EAST: CRO SERVICES MARKET FOR STABILITY TESTING, BY REGION, 2024–2031 (USD MILLION) 177 TABLE 149 GCC COUNTRIES: CRO SERVICES MARKET FOR STABILITY TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 177 TABLE 150 OTHER ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 178 TABLE 151 NORTH AMERICA: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 178 TABLE 152 EUROPE: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 179 TABLE 153 ASIA PACIFIC: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 179 TABLE 154 LATIN AMERICA: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 180 TABLE 155 MIDDLE EAST: OTHER ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 180 TABLE 156 GCC COUNTRIES: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 180 TABLE 157 BIOANALYTICAL TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 181 TABLE 158 NORTH AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 181 TABLE 159 EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 182 TABLE 160 ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 182 TABLE 161 LATIN AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 183 TABLE 162 MIDDLE EAST: BIOANALYTICAL TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 183 TABLE 163 GCC COUNTRIES: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 183 TABLE 164 CONSULTING SERVICES OFFERED BY PROMINENT PLAYERS 184 TABLE 165 CONSULTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 185 TABLE 166 NORTH AMERICA: CONSULTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 186 TABLE 167 EUROPE: CONSULTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 186 TABLE 168 ASIA PACIFIC: CONSULTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 186 TABLE 169 LATIN AMERICA: CONSULTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 187 TABLE 170 MIDDLE EAST: CONSULTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 187 TABLE 171 GCC COUNTRIES: CONSULTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 187 TABLE 172 DATA MANAGEMENT SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 188 TABLE 173 NORTH AMERICA: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 188 TABLE 174 EUROPE: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 189 TABLE 175 ASIA PACIFIC: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 189 TABLE 176 LATIN AMERICA: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 190 TABLE 177 MIDDLE EAST: DATA MANAGEMENT SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 190 TABLE 178 GCC COUNTRIES: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 190 TABLE 179 CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION) 192 TABLE 180 CRO SERVICES MARKET FOR FSO MODEL, BY REGION, 2024–2031 (USD MILLION) 193 TABLE 181 NORTH AMERICA: CRO SERVICES MARKET FOR FSO MODEL, BY COUNTRY, 2024–2031 (USD MILLION) 193 TABLE 182 EUROPE: CRO SERVICES MARKET FOR FSO MODEL, BY COUNTRY, 2024–2031 (USD MILLION) 193 TABLE 183 ASIA PACIFIC: CRO SERVICES MARKET FOR FSO MODEL, BY COUNTRY, 2024–2031 (USD MILLION) 194 TABLE 184 LATIN AMERICA: CRO SERVICES MARKET FOR FSO MODEL, BY COUNTRY, 2024–2031 (USD MILLION) 194 TABLE 185 MIDDLE EAST: CRO SERVICES MARKET FOR FSO MODEL, BY REGION, 2024–2031 (USD MILLION) 194 TABLE 186 GCC COUNTRIES: CRO SERVICES MARKET FOR FSO MODEL, BY COUNTRY, 2024–2031 (USD MILLION) 195 TABLE 187 CRO SERVICES MARKET FOR FSP MODEL, BY REGION, 2024–2031 (USD MILLION) 196 TABLE 188 NORTH AMERICA: CRO SERVICES MARKET FOR FSP MODEL, BY COUNTRY, 2024–2031 (USD MILLION) 196 TABLE 189 EUROPE: CRO SERVICES MARKET FOR FSP MODEL, BY COUNTRY, 2024–2031 (USD MILLION) 196 TABLE 190 ASIA PACIFIC: CRO SERVICES MARKET FOR FSP MODEL, BY COUNTRY, 2024–2031 (USD MILLION) 197 TABLE 191 LATIN AMERICA: CRO SERVICES MARKET FOR FSP MODEL, BY COUNTRY, 2024–2031 (USD MILLION) 197 TABLE 192 MIDDLE EAST: CRO SERVICES MARKET FOR FSP MODEL, BY REGION, 2024–2031 (USD MILLION) 197 TABLE 193 GCC COUNTRIES: CRO SERVICES MARKET FOR FSP MODEL, BY COUNTRY, 2024–2031 (USD MILLION) 198 TABLE 194 CRO SERVICES MARKET FOR HYBRID MODEL, BY REGION, 2024–2031 (USD MILLION) 198 TABLE 195 NORTH AMERICA: CRO SERVICES MARKET FOR HYBRID MODEL, BY COUNTRY, 2024–2031 (USD MILLION) 199 TABLE 196 EUROPE: CRO SERVICES MARKET FOR HYBRID MODEL, BY COUNTRY, 2024–2031 (USD MILLION) 199 TABLE 197 ASIA PACIFIC: CRO SERVICES MARKET FOR HYBRID MODEL, BY COUNTRY, 2024–2031 (USD MILLION) 199 TABLE 198 LATIN AMERICA: CRO SERVICES MARKET FOR HYBRID MODEL, BY COUNTRY, 2024–2031 (USD MILLION) 200 TABLE 199 MIDDLE EAST: CRO SERVICES MARKET FOR HYBRID MODEL, BY COUNTRY, 2024–2031 (USD MILLION) 200 TABLE 200 GCC COUNTRIES: CRO SERVICES MARKET FOR HYBRID MODEL, BY COUNTRY, 2024–2031 (USD MILLION) 200 TABLE 201 CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION) 202 TABLE 202 CRO SERVICES MARKET FOR SMALL MOLECULES, BY REGION, 2024–2031 (USD MILLION) 203 TABLE 203 NORTH AMERICA: CRO SERVICES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2024–2031 (USD MILLION) 203 TABLE 204 EUROPE: CRO SERVICES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2024–2031 (USD MILLION) 204 TABLE 205 ASIA PACIFIC: CRO SERVICES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2024–2031 (USD MILLION) 204 TABLE 206 LATIN AMERICA: CRO SERVICES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2024–2031 (USD MILLION) 205 TABLE 207 MIDDLE EAST: CRO SERVICES MARKET FOR SMALL MOLECULES, BY REGION, 2024–2031 (USD MILLION) 205 TABLE 208 GCC COUNTRIES: CRO SERVICES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2024–2031 (USD MILLION) 205 TABLE 209 CRO SERVICES MARKET FOR BIOLOGICS, BY REGION, 2024–2031 (USD MILLION) 206 TABLE 210 NORTH AMERICA: CRO SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2024–2031 (USD MILLION) 206 TABLE 211 EUROPE: CRO SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2024–2031 (USD MILLION) 207 TABLE 212 ASIA PACIFIC: CRO SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2024–2031 (USD MILLION) 207 TABLE 213 LATIN AMERICA: CRO SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2024–2031 (USD MILLION) 208 TABLE 214 MIDDLE EAST: CRO SERVICES MARKET FOR BIOLOGICS, BY REGION, 2024–2031 (USD MILLION) 208 TABLE 215 GCC COUNTRIES: CRO SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2024–2031 (USD MILLION) 208 TABLE 216 CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION) 209 TABLE 217 CRO SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2024–2031 (USD MILLION) 210 TABLE 218 NORTH AMERICA: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION) 210 TABLE 219 EUROPE: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION) 211 TABLE 220 ASIA PACIFIC: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION) 211 TABLE 221 LATIN AMERICA: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION) 212 TABLE 222 MIDDLE EAST: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2024–2031 (USD MILLION) 212 TABLE 223 GCC COUNTRIES: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION) 212 TABLE 224 CRO SERVICES MARKET FOR CELL & GENE THERAPY, BY REGION, 2024–2031 (USD MILLION) 213 TABLE 225 NORTH AMERICA: CRO SERVICES MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2024–2031 (USD MILLION) 214 TABLE 226 EUROPE: CRO SERVICES MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2024–2031 (USD MILLION) 214 TABLE 227 ASIA PACIFIC: CRO SERVICES MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2024–2031 (USD MILLION) 214 TABLE 228 LATIN AMERICA: CRO SERVICES MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2024–2031 (USD MILLION) 215 TABLE 229 MIDDLE EAST: CRO SERVICES MARKET FOR CELL & GENE THERAPY, BY REGION, 2024–2031 (USD MILLION) 215 TABLE 230 GCC COUNTRIES: CRO SERVICES MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2024–2031 (USD MILLION) 215 TABLE 231 CRO SERVICES MARKET FOR OTHER BIOLOGICS, BY REGION, 2024–2031 (USD MILLION) 216 TABLE 232 NORTH AMERICA: CRO SERVICES MARKET FOR OTHER BIOLOGICS, BY COUNTRY, 2024–2031 (USD MILLION) 216 TABLE 233 EUROPE: CRO SERVICES MARKET FOR OTHER BIOLOGICS, BY COUNTRY, 2024–2031 (USD MILLION) 217 TABLE 234 ASIA PACIFIC: CRO SERVICES MARKET FOR OTHER BIOLOGICS, BY COUNTRY, 2024–2031 (USD MILLION) 217 TABLE 235 LATIN AMERICA: CRO SERVICES MARKET FOR OTHER BIOLOGICS, BY COUNTRY, 2024–2031 (USD MILLION) 218 TABLE 236 MIDDLE EAST: CRO SERVICES MARKET FOR OTHER BIOLOGICS, BY REGION, 2024–2031 (USD MILLION) 218 TABLE 237 GCC COUNTRIES: CRO SERVICES MARKET FOR OTHER BIOLOGICS, BY COUNTRY, 2024–2031 (USD MILLION) 218 TABLE 238 CRO SERVICES MARKET FOR MEDICAL DEVICES, BY REGION, 2024–2031 (USD MILLION) 219 TABLE 239 NORTH AMERICA: CRO SERVICES MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2024–2031 (USD MILLION) 220 TABLE 240 EUROPE: CRO SERVICES MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2024–2031 (USD MILLION) 220 TABLE 241 ASIA PACIFIC: CRO SERVICES MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2024–2031 (USD MILLION) 220 TABLE 242 LATIN AMERICA: CRO SERVICES MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2024–2031 (USD MILLION) 221 TABLE 243 MIDDLE EAST: CRO SERVICES MARKET FOR MEDICAL DEVICES, BY REGION, 2024–2031 (USD MILLION) 221 TABLE 244 GCC COUNTRIES: CRO SERVICES MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2024–2031 (USD MILLION) 221 TABLE 245 CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION) 222 TABLE 246 CRO SERVICES MARKET FOR BIOSIMILARS, BY REGION, 2024–2031 (USD MILLION) 222 TABLE 247 NORTH AMERICA: CRO SERVICES MARKET FOR BIOSIMILARS, BY COUNTRY, 2024–2031 (USD MILLION) 223 TABLE 248 EUROPE: CRO SERVICES MARKET FOR BIOSIMILARS, BY COUNTRY, 2024–2031 (USD MILLION) 223 TABLE 249 ASIA PACIFIC: CRO SERVICES MARKET FOR BIOSIMILARS, BY COUNTRY, 2024–2031 (USD MILLION) 223 TABLE 250 LATIN AMERICA: CRO SERVICES MARKET FOR BIOSIMILARS, BY COUNTRY, 2024–2031 (USD MILLION) 224 TABLE 251 MIDDLE EAST: CRO SERVICES MARKET FOR BIOSIMILARS, BY REGION, 2024–2031 (USD MILLION) 224 TABLE 252 GCC COUNTRIES: CRO SERVICES MARKET FOR BIOSIMILARS, BY COUNTRY, 2024–2031 (USD MILLION) 224 TABLE 253 CRO SERVICES MARKET FOR MONOCLONAL ANTIBODY BIOSIMILARS, BY REGION, 2024–2031 (USD MILLION) 225 TABLE 254 NORTH AMERICA: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODY BIOSIMILARS, BY COUNTRY, 2024–2031 (USD MILLION) 225 TABLE 255 EUROPE: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODY BIOSIMILARS, BY COUNTRY, 2024–2031 (USD MILLION) 226 TABLE 256 ASIA PACIFIC: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODY BIOSIMILARS, BY COUNTRY, 2024–2031 (USD MILLION) 226 TABLE 257 LATIN AMERICA: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODY BIOSIMILARS, BY COUNTRY, 2024–2031 (USD MILLION) 227 TABLE 258 MIDDLE EAST: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODY BIOSIMILARS, BY REGION, 2024–2031 (USD MILLION) 227 TABLE 259 GCC COUNTRIES: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODY BIOSIMILARS, BY COUNTRY, 2024–2031 (USD MILLION) 227 TABLE 260 CRO SERVICES MARKET FOR INSULIN, BY REGION, 2024–2031 (USD MILLION) 228 TABLE 261 NORTH AMERICA: CRO SERVICES MARKET FOR INSULIN, BY COUNTRY, 2024–2031 (USD MILLION) 228 TABLE 262 EUROPE: CRO SERVICES MARKET FOR INSULIN, BY COUNTRY, 2024–2031 (USD MILLION) 229 TABLE 263 ASIA PACIFIC: CRO SERVICES MARKET FOR INSULIN, BY COUNTRY, 2024–2031 (USD MILLION) 229 TABLE 264 LATIN AMERICA: CRO SERVICES MARKET FOR INSULIN, BY COUNTRY, 2024–2031 (USD MILLION) 230 TABLE 265 MIDDLE EAST: CRO SERVICES MARKET FOR INSULIN, BY REGION, 2024–2031 (USD MILLION) 230 TABLE 266 GCC COUNTRIES: CRO SERVICES MARKET FOR INSULIN, BY COUNTRY, 2024–2031 (USD MILLION) 230 TABLE 267 CRO SERVICES MARKET FOR COLONY-STIMULATING FACTORS, BY REGION, 2024–2031 (USD MILLION) 231 TABLE 268 NORTH AMERICA: CRO SERVICES MARKET FOR COLONY-STIMULATING FACTORS, BY COUNTRY, 2024–2031 (USD MILLION) 231 TABLE 269 EUROPE: CRO SERVICES MARKET FOR COLONY-STIMULATING FACTORS, BY COUNTRY, 2024–2031 (USD MILLION) 232 TABLE 270 ASIA PACIFIC: CRO SERVICES MARKET FOR COLONY-STIMULATING FACTORS, BY COUNTRY, 2024–2031 (USD MILLION) 232 TABLE 271 LATIN AMERICA: CRO SERVICES MARKET FOR COLONY-STIMULATING FACTORS, BY COUNTRY, 2024–2031 (USD MILLION) 233 TABLE 272 MIDDLE EAST: CRO SERVICES MARKET FOR COLONY-STIMULATING FACTORS, BY REGION, 2024–2031 (USD MILLION) 233 TABLE 273 GCC COUNTRIES: CRO SERVICES MARKET FOR COLONY-STIMULATING FACTORS, BY COUNTRY, 2024–2031 (USD MILLION) 233 TABLE 274 CRO SERVICES MARKET FOR ERYTHROPOIETIN, BY REGION, 2024–2031 (USD MILLION) 234 TABLE 275 NORTH AMERICA: CRO SERVICES MARKET FOR ERYTHROPOIETIN, BY COUNTRY, 2024–2031 (USD MILLION) 234 TABLE 276 EUROPE: CRO SERVICES MARKET FOR ERYTHROPOIETIN, BY COUNTRY, 2024–2031 (USD MILLION) 235 TABLE 277 ASIA PACIFIC: CRO SERVICES MARKET FOR ERYTHROPOIETIN, BY COUNTRY, 2024–2031 (USD MILLION) 235 TABLE 278 LATIN AMERICA: CRO SERVICES MARKET FOR ERYTHROPOIETIN, BY COUNTRY, 2024–2031 (USD MILLION) 236 TABLE 279 MIDDLE EAST: CRO SERVICES MARKET FOR ERYTHROPOIETIN, BY REGION, 2024–2031 (USD MILLION) 236 TABLE 280 GCC COUNTRIES: CRO SERVICES MARKET FOR ERYTHROPOIETIN, BY COUNTRY, 2024–2031 (USD MILLION) 236 TABLE 281 CRO SERVICES MARKET FOR OTHER BIOSIMILARS, BY REGION, 2024–2031 (USD MILLION) 237 TABLE 282 NORTH AMERICA: CRO SERVICES MARKET FOR OTHER BIOSIMILARS, BY COUNTRY, 2024–2031 (USD MILLION) 237 TABLE 283 EUROPE: CRO SERVICES MARKET FOR OTHER BIOSIMILARS, BY COUNTRY, 2024–2031 (USD MILLION) 238 TABLE 284 ASIA PACIFIC: CRO SERVICES MARKET FOR OTHER BIOSIMILARS, BY COUNTRY, 2024–2031 (USD MILLION) 238 TABLE 285 LATIN AMERICA: CRO SERVICES MARKET FOR OTHER BIOSIMILARS, BY COUNTRY, 2024–2031 (USD MILLION) 239 TABLE 286 MIDDLE EAST: CRO SERVICES MARKET FOR OTHER BIOSIMILARS, BY REGION, 2024–2031 (USD MILLION) 239 TABLE 287 GCC COUNTRIES: CRO SERVICES MARKET FOR OTHER BIOSIMILARS, BY COUNTRY, 2024–2031 (USD MILLION) 239 TABLE 288 CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 241 TABLE 289 NUMBER OF NEW CANCER CASES, BY TYPE, 2020 VS. 2040 242 TABLE 290 CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 243 TABLE 291 CRO SERVICES MARKET FOR ONCOLOGY, BY REGION, 2024–2031 (USD MILLION) 244 TABLE 292 NORTH AMERICA: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 244 TABLE 293 EUROPE: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 244 TABLE 294 ASIA PACIFIC: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 245 TABLE 295 LATIN AMERICA: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 245 TABLE 296 MIDDLE EAST: CRO SERVICES MARKET FOR ONCOLOGY, BY REGION, 2024–2031 (USD MILLION) 245 TABLE 297 GCC COUNTRIES: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 246 TABLE 298 CRO SERVICES MARKET FOR BREAST CANCER, BY REGION, 2024–2031 (USD MILLION) 247 TABLE 299 NORTH AMERICA: CRO SERVICES MARKET FOR BREAST CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 247 TABLE 300 EUROPE: CRO SERVICES MARKET FOR BREAST CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 247 TABLE 301 ASIA PACIFIC: CRO SERVICES MARKET FOR BREAST CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 248 TABLE 302 LATIN AMERICA: CRO SERVICES MARKET FOR BREAST CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 248 TABLE 303 MIDDLE EAST: CRO SERVICES MARKET FOR BREAST CANCER, BY REGION, 2024–2031 (USD MILLION) 248 TABLE 304 GCC COUNTRIES: CRO SERVICES MARKET FOR BREAST CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 249 TABLE 305 CRO SERVICES MARKET FOR LUNG CANCER, BY REGION, 2024–2031 (USD MILLION) 249 TABLE 306 NORTH AMERICA: CRO SERVICES MARKET FOR LUNG CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 250 TABLE 307 EUROPE: CRO SERVICES MARKET FOR LUNG CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 250 TABLE 308 ASIA PACIFIC: CRO SERVICES MARKET FOR LUNG CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 250 TABLE 309 LATIN AMERICA: CRO SERVICES MARKET FOR LUNG CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 251 TABLE 310 MIDDLE EAST: CRO SERVICES MARKET FOR LUNG CANCER, BY REGION, 2024–2031 (USD MILLION) 251 TABLE 311 GCC COUNTRIES: CRO SERVICES MARKET FOR LUNG CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 251 TABLE 312 CRO SERVICES MARKET FOR COLORECTAL CANCER, BY REGION, 2024–2031 (USD MILLION) 252 TABLE 313 NORTH AMERICA: CRO SERVICES MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 253 TABLE 314 EUROPE: CRO SERVICES MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 253 TABLE 315 ASIA PACIFIC: CRO SERVICES MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 253 TABLE 316 LATIN AMERICA: CRO SERVICES MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 254 TABLE 317 MIDDLE EAST: CRO SERVICES MARKET FOR COLORECTAL CANCER, BY REGION, 2024–2031 (USD MILLION) 254 TABLE 318 GCC COUNTRIES: CRO SERVICES MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 254 TABLE 319 CRO SERVICES MARKET FOR PROSTATE CANCER, BY REGION, 2024–2031 (USD MILLION) 255 TABLE 320 NORTH AMERICA: CRO SERVICES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 256 TABLE 321 EUROPE: CRO SERVICES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 256 TABLE 322 ASIA PACIFIC: CRO SERVICES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 256 TABLE 323 LATIN AMERICA: CRO SERVICES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 257 TABLE 324 MIDDLE EAST: CRO SERVICES MARKET FOR PROSTATE CANCER, BY REGION, 2024–2031 (USD MILLION) 257 TABLE 325 GCC COUNTRIES: CRO SERVICES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 257 TABLE 326 NUMBER OF DRUGS IN R&D PIPELINE FOR OTHER CANCERS, 2023–2025 258 TABLE 327 CRO SERVICES MARKET FOR OTHER CANCERS, BY REGION, 2024–2031 (USD MILLION) 258 TABLE 328 NORTH AMERICA: CRO SERVICES MARKET FOR OTHER CANCERS, BY COUNTRY, 2024–2031 (USD MILLION) 258 TABLE 329 EUROPE: CRO SERVICES MARKET FOR OTHER CANCERS, BY COUNTRY, 2024–2031 (USD MILLION) 259 TABLE 330 ASIA PACIFIC: CRO SERVICES MARKET FOR OTHER CANCERS, BY COUNTRY, 2024–2031 (USD MILLION) 259 TABLE 331 LATIN AMERICA: CRO SERVICES MARKET FOR OTHER CANCERS, BY COUNTRY, 2024–2031 (USD MILLION) 259 TABLE 332 MIDDLE EAST: CRO SERVICES MARKET FOR OTHER CANCERS, BY REGION, 2024–2031 (USD MILLION) 260 TABLE 333 GCC COUNTRIES: CRO SERVICES MARKET FOR OTHER CANCERS, BY COUNTRY, 2024–2031 (USD MILLION) 260 TABLE 334 CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2024–2031 (USD MILLION) 261 TABLE 335 NORTH AMERICA: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 261 TABLE 336 EUROPE: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 262 TABLE 337 ASIA PACIFIC: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 262 TABLE 338 LATIN AMERICA: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 263 TABLE 339 MIDDLE EAST: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2024–2031 (USD MILLION) 263 TABLE 340 GCC COUNTRIES: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 263 TABLE 341 CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY REGION, 2024–2031 (USD MILLION) 264 TABLE 342 NORTH AMERICA: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 265 TABLE 343 EUROPE: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 265 TABLE 344 ASIA PACIFIC: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 265 TABLE 345 LATIN AMERICA: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 266 TABLE 346 MIDDLE EAST: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY REGION, 2024–2031 (USD MILLION) 266 TABLE 347 GCC COUNTRIES: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 266 TABLE 348 CRO SERVICES MARKET FOR NEUROLOGY, BY REGION, 2024–2031 (USD MILLION) 267 TABLE 349 NORTH AMERICA: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 268 TABLE 350 EUROPE: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 268 TABLE 351 ASIA PACIFIC: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 268 TABLE 352 LATIN AMERICA: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 269 TABLE 353 MIDDLE EAST: CRO SERVICES MARKET FOR NEUROLOGY, BY REGION, 2024–2031 (USD MILLION) 269 TABLE 354 GCC COUNTRIES: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 269 TABLE 355 CRO SERVICES MARKET FOR VACCINES, BY REGION, 2024–2031 (USD MILLION) 270 TABLE 356 NORTH AMERICA: CRO SERVICES MARKET FOR VACCINES, BY COUNTRY, 2024–2031 (USD MILLION) 270 TABLE 357 EUROPE: CRO SERVICES MARKET FOR VACCINES, BY COUNTRY, 2024–2031 (USD MILLION) 271 TABLE 358 ASIA PACIFIC: CRO SERVICES MARKET FOR VACCINES, BY COUNTRY, 2024–2031 (USD MILLION) 271 TABLE 359 LATIN AMERICA: CRO SERVICES MARKET FOR VACCINES, BY COUNTRY, 2024–2031 (USD MILLION) 271 TABLE 360 MIDDLE EAST: CRO SERVICES MARKET FOR VACCINES, BY REGION, 2024–2031 (USD MILLION) 272 TABLE 361 GCC COUNTRIES: CRO SERVICES MARKET FOR VACCINES, BY COUNTRY, 2024–2031 (USD MILLION) 272 TABLE 362 CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY REGION, 2024–2031 (USD MILLION) 274 TABLE 363 NORTH AMERICA: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 274 TABLE 364 EUROPE: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 274 TABLE 365 ASIA PACIFIC: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 275 TABLE 366 LATIN AMERICA: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 275 TABLE 367 MIDDLE EAST: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY REGION, 2024–2031 (USD MILLION) 275 TABLE 368 GCC COUNTRIES: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 276 TABLE 369 CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2024–2031 (USD MILLION) 277 TABLE 370 NORTH AMERICA: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 277 TABLE 371 EUROPE: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 277 TABLE 372 ASIA PACIFIC: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 278 TABLE 373 LATIN AMERICA: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 278 TABLE 374 MIDDLE EAST: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2024–2031 (USD MILLION) 278 TABLE 375 GCC COUNTRIES: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 279 TABLE 376 CRO SERVICES MARKET FOR PSYCHIATRY, BY REGION, 2024–2031 (USD MILLION) 280 TABLE 377 NORTH AMERICA: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2024–2031 (USD MILLION) 280 TABLE 378 EUROPE: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2024–2031 (USD MILLION) 280 TABLE 379 ASIA PACIFIC: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2024–2031 (USD MILLION) 281 TABLE 380 LATIN AMERICA: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2024–2031 (USD MILLION) 281 TABLE 381 MIDDLE EAST: CRO SERVICES MARKET FOR PSYCHIATRY, BY REGION, 2024–2031 (USD MILLION) 281 TABLE 382 GCC COUNTRIES: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2024–2031 (USD MILLION) 282 TABLE 383 CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY REGION, 2024–2031 (USD MILLION) 283 TABLE 384 NORTH AMERICA: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 283 TABLE 385 EUROPE: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 283 TABLE 386 ASIA PACIFIC: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 284 TABLE 387 LATIN AMERICA: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 284 TABLE 388 MIDDLE EAST: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY REGION, 2024–2031 (USD MILLION) 284 TABLE 389 GCC COUNTRIES: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 285 TABLE 390 CRO SERVICES MARKET FOR DERMATOLOGY, BY REGION, 2024–2031 (USD MILLION) 286 TABLE 391 NORTH AMERICA: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 286 TABLE 392 EUROPE: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 286 TABLE 393 ASIA PACIFIC: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 287 TABLE 394 LATIN AMERICA: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 287 TABLE 395 MIDDLE EAST: CRO SERVICES MARKET FOR DERMATOLOGY, BY REGION, 2024–2031 (USD MILLION) 287 TABLE 396 GCC COUNTRIES: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 288 TABLE 397 CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY REGION, 2024–2031 (USD MILLION) 288 TABLE 398 NORTH AMERICA: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 289 TABLE 399 EUROPE: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 289 TABLE 400 ASIA PACIFIC: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 289 TABLE 401 LATIN AMERICA: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 290 TABLE 402 MIDDLE EAST: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY REGION, 2024–2031 (USD MILLION) 290 TABLE 403 GCC COUNTRIES: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 290 TABLE 404 CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2024–2031 (USD MILLION) 291 TABLE 405 NORTH AMERICA: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 291 TABLE 406 EUROPE: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 292 TABLE 407 ASIA PACIFIC: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 292 TABLE 408 LATIN AMERICA: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 293 TABLE 409 MIDDLE EAST: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2024–2031 (USD MILLION) 293 TABLE 410 GCC COUNTRIES: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 293 TABLE 411 CRO SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY REGION, 2024–2031 (USD MILLION) 294 TABLE 412 NORTH AMERICA: CRO SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2024–2031 (USD MILLION) 295 TABLE 413 EUROPE: CRO SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2024–2031 (USD MILLION) 295 TABLE 414 ASIA PACIFIC: CRO SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2024–2031 (USD MILLION) 295 TABLE 415 LATIN AMERICA: CRO SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2024–2031 (USD MILLION) 296 TABLE 416 MIDDLE EAST: CRO SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY REGION, 2024–2031 (USD MILLION) 296 TABLE 417 GCC COUNTRIES: CRO SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2024–2031 (USD MILLION) 296 TABLE 418 CRO SERVICES MARKET FOR HEMATOLOGY, BY REGION, 2024–2031 (USD MILLION) 297 TABLE 419 NORTH AMERICA: CRO SERVICES MARKET FOR HEMATOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 297 TABLE 420 EUROPE: CRO SERVICES MARKET FOR HEMATOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 298 TABLE 421 ASIA PACIFIC: CRO SERVICES MARKET FOR HEMATOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 298 TABLE 422 LATIN AMERICA: CRO SERVICES MARKET FOR HEMATOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 298 TABLE 423 MIDDLE EAST: CRO SERVICES MARKET FOR HEMATOLOGY, BY REGION, 2024–2031 (USD MILLION) 299 TABLE 424 GCC COUNTRIES: CRO SERVICES MARKET FOR HEMATOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 299 TABLE 425 CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2024–2031 (USD MILLION) 300 TABLE 426 NORTH AMERICA: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024–2031 (USD MILLION) 300 TABLE 427 EUROPE: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024–2031 (USD MILLION) 300 TABLE 428 ASIA PACIFIC: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024–2031 (USD MILLION) 301 TABLE 429 LATIN AMERICA: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024–2031 (USD MILLION) 301 TABLE 430 MIDDLE EAST: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2024–2031 (USD MILLION) 301 TABLE 431 GCC COUNTRIES: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024–2031 (USD MILLION) 302 TABLE 432 CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 304 TABLE 433 CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 306 TABLE 434 CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2024–2031 (USD MILLION) 306 TABLE 435 NORTH AMERICA: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 307 TABLE 436 EUROPE: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 307 TABLE 437 ASIA PACIFIC: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 307 TABLE 438 LATIN AMERICA: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 308 TABLE 439 MIDDLE EAST: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2024–2031 (USD MILLION) 308 TABLE 440 GCC COUNTRIES: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 308 TABLE 441 CRO SERVICES MARKET FOR LARGE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2024–2031 (USD MILLION) 309 TABLE 442 NORTH AMERICA: CRO SERVICES MARKET FOR LARGE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 309 TABLE 443 EUROPE: CRO SERVICES MARKET FOR LARGE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 310 TABLE 444 ASIA PACIFIC: CRO SERVICES MARKET FOR LARGE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 310 TABLE 445 LATIN AMERICA: CRO SERVICES MARKET FOR LARGE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 311 TABLE 446 MIDDLE EAST: CRO SERVICES MARKET FOR LARGE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2024–2031 (USD MILLION) 311 TABLE 447 GCC COUNTRIES: CRO SERVICES MARKET FOR LARGE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 311 TABLE 448 CRO SERVICES MARKET FOR SMALL & MID-SIZE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2024–2031 (USD MILLION) 312 TABLE 449 NORTH AMERICA: CRO SERVICES MARKET FOR SMALL & MID-SIZE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 312 TABLE 450 EUROPE: CRO SERVICES MARKET FOR SMALL & MID-SIZE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 313 TABLE 451 ASIA PACIFIC: CRO SERVICES MARKET FOR SMALL & MID-SIZE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 313 TABLE 452 LATIN AMERICA: CRO SERVICES MARKET FOR SMALL & MID-SIZE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 314 TABLE 453 MIDDLE EAST: CRO SERVICES MARKET FOR SMALL & MID-SIZE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2024–2031 (USD MILLION) 314 TABLE 454 GCC COUNTRIES: CRO SERVICES MARKET FOR SMALL & MID-SIZE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 314 TABLE 455 CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY REGION, 2024–2031 (USD MILLION) 316 TABLE 456 NORTH AMERICA: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 316 TABLE 457 EUROPE: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 316 TABLE 458 ASIA PACIFIC: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 317 TABLE 459 LATIN AMERICA: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 317 TABLE 460 MIDDLE EAST: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY REGION, 2024–2031 (USD MILLION) 317 TABLE 461 GCC COUNTRIES: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 318 TABLE 462 CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2024–2031 (USD MILLION) 319 TABLE 463 NORTH AMERICA: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 319 TABLE 464 EUROPE: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 320 TABLE 465 ASIA PACIFIC: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 320 TABLE 466 LATIN AMERICA: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 321 TABLE 467 MIDDLE EAST: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2024–2031 (USD MILLION) 321 TABLE 468 GCC COUNTRIES: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 321 TABLE 469 CRO SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 323 TABLE 470 NORTH AMERICA: CRO SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 324 TABLE 471 NORTH AMERICA: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 325 TABLE 472 NORTH AMERICA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION) 325 TABLE 473 NORTH AMERICA: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION) 326 TABLE 474 NORTH AMERICA: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION) 326 TABLE 475 NORTH AMERICA: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION) 326 TABLE 476 NORTH AMERICA: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION) 327 TABLE 477 NORTH AMERICA: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION) 327 TABLE 478 NORTH AMERICA: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION) 327 TABLE 479 NORTH AMERICA: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION) 328 TABLE 480 NORTH AMERICA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 328 TABLE 481 NORTH AMERICA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 329 TABLE 482 NORTH AMERICA: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION) 329 TABLE 483 NORTH AMERICA: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 330 TABLE 484 NORTH AMERICA: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 330 TABLE 485 US: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 332 TABLE 486 US: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION) 332 TABLE 487 US: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION) 332 TABLE 488 US: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION) 333 TABLE 489 US: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION) 333 TABLE 490 US: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION) 333 TABLE 491 US: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION) 334 TABLE 492 US: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION) 334 TABLE 493 US: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION) 334 TABLE 494 US: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 335 TABLE 495 US: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 335 TABLE 496 US: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION) 336 TABLE 497 US: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 336 TABLE 498 US: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 336 TABLE 499 CANADA: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 337 TABLE 500 CANADA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION) 338 TABLE 501 CANADA: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION) 338 TABLE 502 CANADA: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION) 338 TABLE 503 CANADA: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION) 339 TABLE 504 CANADA: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION) 339 TABLE 505 CANADA: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION) 339 TABLE 506 CANADA: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION) 340 TABLE 507 CANADA: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION) 340 TABLE 508 CANADA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 341 TABLE 509 CANADA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 341 TABLE 510 CANADA: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION) 342 TABLE 511 CANADA: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 342 TABLE 512 CANADA: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 342 TABLE 513 EUROPE: CRO SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 343 TABLE 514 EUROPE: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 344 TABLE 515 EUROPE: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION) 344 TABLE 516 EUROPE: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION) 344 TABLE 517 EUROPE: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION) 345 TABLE 518 EUROPE: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION) 345 TABLE 519 EUROPE: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION) 345 TABLE 520 EUROPE: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION) 346 TABLE 521 EUROPE: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION) 346 TABLE 522 EUROPE: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION) 346 TABLE 523 EUROPE: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 347 TABLE 524 EUROPE: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 347 TABLE 525 EUROPE: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION) 348 TABLE 526 EUROPE: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 348 TABLE 527 EUROPE: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 348 TABLE 528 GERMANY: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 349 TABLE 529 GERMANY: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION) 350 TABLE 530 GERMANY: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION) 350 TABLE 531 GERMANY: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION) 350 TABLE 532 GERMANY: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION) 351 TABLE 533 GERMANY: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION) 351 TABLE 534 GERMANY: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION) 351 TABLE 535 GERMANY: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION) 352 TABLE 536 GERMANY: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION) 352 TABLE 537 GERMANY: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 353 TABLE 538 GERMANY: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 353 TABLE 539 GERMANY: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION) 354 TABLE 540 GERMANY: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 354 TABLE 541 GERMANY: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 354 TABLE 542 UK: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 355 TABLE 543 UK: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION) 356 TABLE 544 UK: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION) 356 TABLE 545 UK: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION) 356 TABLE 546 UK: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION) 357 TABLE 547 UK: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION) 357 TABLE 548 UK: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION) 357 TABLE 549 UK: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION) 358 TABLE 550 UK: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION) 358 TABLE 551 UK: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 359 TABLE 552 UK: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 359 TABLE 553 UK: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION) 360 TABLE 554 UK: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 360 TABLE 555 UK: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 360 TABLE 556 FRANCE: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 361 TABLE 557 FRANCE: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION) 361 TABLE 558 FRANCE: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION) 362 TABLE 559 FRANCE: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION) 362 TABLE 560 FRANCE: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION) 362 TABLE 561 FRANCE: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION) 363 TABLE 562 FRANCE: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION) 363 TABLE 563 FRANCE: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION) 363 TABLE 564 FRANCE: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION) 364 TABLE 565 FRANCE: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 364 TABLE 566 FRANCE: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 365 TABLE 567 FRANCE: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION) 365 TABLE 568 FRANCE: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 365 TABLE 569 FRANCE: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 366 TABLE 570 ITALY: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 366 TABLE 571 ITALY: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION) 367 TABLE 572 ITALY: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION) 367 TABLE 573 ITALY: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION) 367 TABLE 574 ITALY: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION) 368 TABLE 575 ITALY: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION) 368 TABLE 576 ITALY: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION) 368 TABLE 577 ITALY: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION) 369 TABLE 578 ITALY: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION) 369 TABLE 579 ITALY: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 370 TABLE 580 ITALY: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 370 TABLE 581 ITALY: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION) 371 TABLE 582 ITALY: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 371 TABLE 583 ITALY: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 371 TABLE 584 SPAIN: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 372 TABLE 585 SPAIN: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION) 372 TABLE 586 SPAIN: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION) 373 TABLE 587 SPAIN: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION) 373 TABLE 588 SPAIN: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION) 373 TABLE 589 SPAIN: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION) 374 TABLE 590 SPAIN: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION) 374 TABLE 591 SPAIN: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION) 374 TABLE 592 SPAIN: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION) 375 TABLE 593 SPAIN: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 375 TABLE 594 SPAIN: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 376 TABLE 595 SPAIN: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION) 376 TABLE 596 SPAIN: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 376 TABLE 597 SPAIN: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 377 TABLE 598 REST OF EUROPE: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 378 TABLE 599 REST OF EUROPE: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION) 378 TABLE 600 REST OF EUROPE: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION) 378 TABLE 601 REST OF EUROPE: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION) 379 TABLE 602 REST OF EUROPE: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION) 379 TABLE 603 REST OF EUROPE: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION) 379 TABLE 604 REST OF EUROPE: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION) 380 TABLE 605 REST OF EUROPE: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION) 380 TABLE 606 REST OF EUROPE: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION) 380 TABLE 607 REST OF EUROPE: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 381 TABLE 608 REST OF EUROPE: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 381 TABLE 609 REST OF EUROPE: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION) 382 TABLE 610 REST OF EUROPE: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 382 TABLE 611 REST OF EUROPE: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 382 TABLE 612 ASIA PACIFIC: CRO SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 384 TABLE 613 ASIA PACIFIC: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 384 TABLE 614 ASIA PACIFIC: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION) 384 TABLE 615 ASIA PACIFIC: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION) 385 TABLE 616 ASIA PACIFIC: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION) 385 TABLE 617 ASIA PACIFIC: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION) 385 TABLE 618 ASIA PACIFIC: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION) 386 TABLE 619 ASIA PACIFIC: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION) 386 TABLE 620 ASIA PACIFIC: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION) 386 TABLE 621 ASIA PACIFIC: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION) 387 TABLE 622 ASIA PACIFIC: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 387 TABLE 623 ASIA PACIFIC: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 388 TABLE 624 ASIA PACIFIC: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION) 388 TABLE 625 ASIA PACIFIC: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 388 TABLE 626 ASIA PACIFIC: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 389 TABLE 627 CHINA: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 390 TABLE 628 CHINA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION) 390 TABLE 629 CHINA: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION) 391 TABLE 630 CHINA: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION) 391 TABLE 631 CHINA: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION) 391 TABLE 632 CHINA: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION) 392 TABLE 633 CHINA: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION) 392 TABLE 634 CHINA: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION) 392 TABLE 635 CHINA: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION) 393 TABLE 636 CHINA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 393 TABLE 637 CHINA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 394 TABLE 638 CHINA: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION) 394 TABLE 639 CHINA: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 394 TABLE 640 CHINA: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 395 TABLE 641 INDIA: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 396 TABLE 642 INDIA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION) 396 TABLE 643 INDIA: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION) 396 TABLE 644 INDIA: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION) 397 TABLE 645 INDIA: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION) 397 TABLE 646 INDIA: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION) 397 TABLE 647 INDIA: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION) 398 TABLE 648 INDIA: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION) 398 TABLE 649 INDIA: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION) 398 TABLE 650 INDIA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 399 TABLE 651 INDIA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 399 TABLE 652 INDIA: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION) 400 TABLE 653 INDIA: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 400 TABLE 654 INDIA: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 400 TABLE 655 JAPAN: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 401 TABLE 656 JAPAN: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION) 402 TABLE 657 JAPAN: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION) 402 TABLE 658 JAPAN: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION) 402 TABLE 659 JAPAN: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION) 403 TABLE 660 JAPAN: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION) 403 TABLE 661 JAPAN: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION) 403 TABLE 662 JAPAN: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION) 404 TABLE 663 JAPAN: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION) 404 TABLE 664 JAPAN: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 405 TABLE 665 JAPAN: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 405 TABLE 666 JAPAN: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION) 406 TABLE 667 JAPAN: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 406 TABLE 668 JAPAN: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 406 TABLE 669 AUSTRALIA: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 407 TABLE 670 AUSTRALIA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION) 408 TABLE 671 AUSTRALIA: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION) 408 TABLE 672 AUSTRALIA: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION) 408 TABLE 673 AUSTRALIA: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION) 409 TABLE 674 AUSTRALIA: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION) 409 TABLE 675 AUSTRALIA: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION) 409 TABLE 676 AUSTRALIA: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION) 410 TABLE 677 AUSTRALIA: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION) 410 TABLE 678 AUSTRALIA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 411 TABLE 679 AUSTRALIA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 411 TABLE 680 AUSTRALIA: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION) 412 TABLE 681 AUSTRALIA: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 412 TABLE 682 AUSTRALIA: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 412 TABLE 683 SOUTH KOREA: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 413 TABLE 684 SOUTH KOREA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION) 414 TABLE 685 SOUTH KOREA: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION) 414 TABLE 686 SOUTH KOREA: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION) 414 TABLE 687 SOUTH KOREA: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION) 415 TABLE 688 SOUTH KOREA: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION) 415 TABLE 689 SOUTH KOREA: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION) 415 TABLE 690 SOUTH KOREA: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION) 416 TABLE 691 SOUTH KOREA: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION) 416 TABLE 692 SOUTH KOREA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 417 TABLE 693 SOUTH KOREA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 417 TABLE 694 SOUTH KOREA: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION) 418 TABLE 695 SOUTH KOREA: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 418 TABLE 696 SOUTH KOREA: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 418 TABLE 697 REST OF ASIA PACIFIC: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 419 TABLE 698 REST OF ASIA PACIFIC: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION) 420 TABLE 699 REST OF ASIA PACIFIC: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION) 420 TABLE 700 REST OF ASIA PACIFIC: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION) 420 TABLE 701 REST OF ASIA PACIFIC: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION) 421 TABLE 702 REST OF ASIA PACIFIC: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION) 421 TABLE 703 REST OF ASIA PACIFIC: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION) 421 TABLE 704 REST OF ASIA PACIFIC: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION) 422 TABLE 705 REST OF ASIA PACIFIC: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION) 422 TABLE 706 REST OF ASIA PACIFIC: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 423 TABLE 707 REST OF ASIA PACIFIC: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 423 TABLE 708 REST OF ASIA PACIFIC: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION) 424 TABLE 709 REST OF ASIA PACIFIC: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 424 TABLE 710 REST OF ASIA PACIFIC: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 424 TABLE 711 LATIN AMERICA: CRO SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 425 TABLE 712 LATIN AMERICA: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 425 TABLE 713 LATIN AMERICA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION) 426 TABLE 714 LATIN AMERICA: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION) 426 TABLE 715 LATIN AMERICA: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION) 426 TABLE 716 LATIN AMERICA: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION) 427 TABLE 717 LATIN AMERICA: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION) 427 TABLE 718 LATIN AMERICA: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION) 427 TABLE 719 LATIN AMERICA: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION) 428 TABLE 720 LATIN AMERICA: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION) 428 TABLE 721 LATIN AMERICA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 429 TABLE 722 LATIN AMERICA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 429 TABLE 723 LATIN AMERICA: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION) 430 TABLE 724 LATIN AMERICA: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 430 TABLE 725 LATIN AMERICA: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 430 TABLE 726 BRAZIL: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 431 TABLE 727 BRAZIL: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION) 431 TABLE 728 BRAZIL: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION) 432 TABLE 729 BRAZIL: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION) 432 TABLE 730 BRAZIL: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION) 432 TABLE 731 BRAZIL: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION) 433 TABLE 732 BRAZIL: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION) 433 TABLE 733 BRAZIL: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION) 433 TABLE 734 BRAZIL: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION) 434 TABLE 735 BRAZIL: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 434 TABLE 736 BRAZIL: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 435 TABLE 737 BRAZIL: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION) 435 TABLE 738 BRAZIL: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 435 TABLE 739 BRAZIL: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 436 TABLE 740 MEXICO: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 436 TABLE 741 MEXICO: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION) 437 TABLE 742 MEXICO: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION) 437 TABLE 743 MEXICO: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION) 437 TABLE 744 MEXICO: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION) 438 TABLE 745 MEXICO: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION) 438 TABLE 746 MEXICO: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION) 438 TABLE 747 MEXICO: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION) 439 TABLE 748 MEXICO: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION) 439 TABLE 749 MEXICO: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 440 TABLE 750 MEXICO: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 440 TABLE 751 MEXICO: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION) 441 TABLE 752 MEXICO: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 441 TABLE 753 MEXICO: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 441 TABLE 754 REST OF LATIN AMERICA: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 442 TABLE 755 REST OF LATIN AMERICA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION) 442 TABLE 756 REST OF LATIN AMERICA: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION) 443 TABLE 757 REST OF LATIN AMERICA: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION) 443 TABLE 758 REST OF LATIN AMERICA: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION) 443 TABLE 759 REST OF LATIN AMERICA: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION) 444 TABLE 760 REST OF LATIN AMERICA: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION) 444 TABLE 761 REST OF LATIN AMERICA: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION) 444 TABLE 762 REST OF LATIN AMERICA: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION) 445 TABLE 763 REST OF LATIN AMERICA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 445 TABLE 764 REST OF LATIN AMERICA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 446 TABLE 765 REST OF LATIN AMERICA: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION) 446 TABLE 766 REST OF LATIN AMERICA: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 446 TABLE 767 REST OF LATIN AMERICA: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 447 TABLE 768 MIDDLE EAST: CRO SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 447 TABLE 769 MIDDLE EAST: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 448 TABLE 770 MIDDLE EAST: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION) 448 TABLE 771 MIDDLE EAST: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION) 448 TABLE 772 MIDDLE EAST: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION) 449 TABLE 773 MIDDLE EAST: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION) 449 TABLE 774 MIDDLE EAST: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION) 449 TABLE 775 MIDDLE EAST: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION) 450 TABLE 776 MIDDLE EAST: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION) 450 TABLE 777 MIDDLE EAST: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION) 450 TABLE 778 MIDDLE EAST: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 451 TABLE 779 MIDDLE EAST: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 451 TABLE 780 MIDDLE EAST: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION) 452 TABLE 781 MIDDLE EAST: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 452 TABLE 782 MIDDLE EAST: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 452 TABLE 783 GCC COUNTRIES: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 453 TABLE 784 GCC COUNTRIES: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 453 TABLE 785 GCC COUNTRIES: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION) 453 TABLE 786 GCC COUNTRIES: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION) 454 TABLE 787 GCC COUNTRIES: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION) 454 TABLE 788 GCC COUNTRIES: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION) 454 TABLE 789 GCC COUNTRIES: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION) 455 TABLE 790 GCC COUNTRIES: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION) 455 TABLE 791 GCC COUNTRIES: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION) 455 TABLE 792 GCC COUNTRIES: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION) 456 TABLE 793 GCC COUNTRIES: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 456 TABLE 794 GCC COUNTRIES: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 457 TABLE 795 GCC COUNTRIES: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION) 457 TABLE 796 GCC COUNTRIES: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 457 TABLE 797 GCC COUNTRIES: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 458 TABLE 798 KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 458 TABLE 799 KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION) 459 TABLE 800 KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION) 459 TABLE 801 KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION) 459 TABLE 802 KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION) 460 TABLE 803 KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION) 460 TABLE 804 KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION) 460 TABLE 805 KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION) 461 TABLE 806 KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION) 461 TABLE 807 KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 462 TABLE 808 KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 462 TABLE 809 KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION) 463 TABLE 810 KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 463 TABLE 811 KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 463 TABLE 812 UNITED ARAB EMIRATES (UAE): CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 464 TABLE 813 UNITED ARAB EMIRATES (UAE): CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION) 465 TABLE 814 UNITED ARAB EMIRATES (UAE): CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION) 465 TABLE 815 UNITED ARAB EMIRATES (UAE): CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION) 465 TABLE 816 UNITED ARAB EMIRATES (UAE): CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION) 466 TABLE 817 UNITED ARAB EMIRATES (UAE): CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION) 466 TABLE 818 UNITED ARAB EMIRATES (UAE): CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION) 466 TABLE 819 UNITED ARAB EMIRATES (UAE): CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION) 467 TABLE 820 UNITED ARAB EMIRATES (UAE): CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION) 467 TABLE 821 UNITED ARAB EMIRATES (UAE): CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 468 TABLE 822 UNITED ARAB EMIRATES (UAE): CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 468 TABLE 823 UNITED ARAB EMIRATES (UAE): CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION) 469 TABLE 824 UNITED ARAB EMIRATES (UAE): CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 469 TABLE 825 UNITED ARAB EMIRATES (UAE): CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 469 TABLE 826 REST OF GCC COUNTRIES: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 470 TABLE 827 REST OF GCC COUNTRIES: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION) 470 TABLE 828 REST OF GCC COUNTRIES: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION) 471 TABLE 829 REST OF GCC COUNTRIES: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION) 471 TABLE 830 REST OF GCC COUNTRIES: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION) 471 TABLE 831 REST OF GCC COUNTRIES: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION) 472 TABLE 832 REST OF GCC COUNTRIES: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION) 472 TABLE 833 REST OF GCC COUNTRIES: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION) 472 TABLE 834 REST OF GCC COUNTRIES: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION) 473 TABLE 835 REST OF GCC COUNTRIES: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 473 TABLE 836 REST OF GCC COUNTRIES: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 474 TABLE 837 REST OF GCC COUNTRIES: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION) 474 TABLE 838 REST OF GCC COUNTRIES: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 474 TABLE 839 REST OF GCC COUNTRIES: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 475 TABLE 840 REST OF MIDDLE EAST: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 475 TABLE 841 REST OF MIDDLE EAST: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION) 476 TABLE 842 REST OF MIDDLE EAST: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION) 476 TABLE 843 REST OF MIDDLE EAST: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION) 476 TABLE 844 REST OF MIDDLE EAST: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION) 477 TABLE 845 REST OF MIDDLE EAST: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION) 477 TABLE 846 REST OF MIDDLE EAST: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION) 477 TABLE 847 REST OF MIDDLE EAST: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION) 478 TABLE 848 REST OF MIDDLE EAST: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION) 478 TABLE 849 REST OF MIDDLE EAST: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 479 TABLE 850 REST OF MIDDLE EAST: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 479 TABLE 851 REST OF MIDDLE EAST: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION) 480 TABLE 852 REST OF MIDDLE EAST: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 480 TABLE 853 REST OF MIDDLE EAST: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 480 TABLE 854 AFRICA: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 481 TABLE 855 AFRICA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION) 481 TABLE 856 AFRICA: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION) 482 TABLE 857 AFRICA: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION) 482 TABLE 858 AFRICA: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION) 482 TABLE 859 AFRICA: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION) 483 TABLE 860 AFRICA: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION) 483 TABLE 861 AFRICA: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION) 483 TABLE 862 AFRICA: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION) 484 TABLE 863 AFRICA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 484 TABLE 864 AFRICA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 485 TABLE 865 AFRICA: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION) 485 TABLE 866 AFRICA: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 485 TABLE 867 AFRICA: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 486 TABLE 868 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN CRO SERVICES MARKET, JANUARY 2023-MARCH 2026 487 TABLE 869 CRO SERVICES MARKET: DEGREE OF COMPETITION 490 TABLE 870 CRO SERVICES MARKET: REGION FOOTPRINT 495 TABLE 871 CRO SERVICES MARKET: TYPE FOOTPRINT 496 TABLE 872 CRO SERVICES MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS 499 TABLE 873 CRO SERVICES MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SME PLAYERS, BY TYPE AND REGION 500 TABLE 874 CRO SERVICES MARKET: SERVICE LAUNCHES, JANUARY 2023–MARCH 2026 503 TABLE 875 CRO SERVICES MARKET: DEALS, JANUARY 2023–MARCH 2026 504 TABLE 876 CRO SERVICES MARKET: EXPANSIONS, JANUARY 2023–MARCH 2026 505 TABLE 877 IQVIA INC.: COMPANY OVERVIEW 506 TABLE 878 IQVIA INC.: SERVICES/SOLUTIONS OFFERED 507 TABLE 879 IQVIA INC.: PRODUCT & SERVICE LAUNCHES, JANUARY 2023–MARCH 2026 509 TABLE 880 IQVIA INC.: DEALS, JANUARY 2023–MARCH 2026 510 TABLE 881 ICON PLC: COMPANY OVERVIEW 513 TABLE 882 ICON PLC.: SERVICES/SOLUTIONS OFFERED 514 TABLE 883 ICON PLC.: SERVICE LAUNCHES, JANUARY 2023–MARCH 2026 516 TABLE 884 ICON PLC: DEALS, JANUARY 2023–MARCH 2026 516 TABLE 885 ICON PLC.: EXPANSIONS, JANUARY 2023–MARCH 2026 517 TABLE 886 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 518 TABLE 887 THERMO FISHER SCIENTIFIC INC.: SERVICES/SOLUTIONS OFFERED 519 TABLE 888 THERMO FISHER SCIENTIFIC, INC.: SERVICE LAUNCHES, JANUARY 2023–MARCH 2026 521 TABLE 889 THERMO FISHER SCIENTIFIC, INC.: DEALS, JANUARY 2021–APRIL 2026 522 TABLE 890 THERMO FISHER SCIENTIFIC, INC.: EXPANSIONS, JANUARY 2023–MARCH 2026 523 TABLE 891 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY OVERVIEW 525 TABLE 892 LABORATORY CORPORATION OF AMERICA HOLDINGS: SERVICES/SOLUTIONS OFFERED 526 TABLE 893 LABORATORY CORPORATION OF AMERICA HOLDINGS: SERVICE LAUNCHES, JANUARY 2023–MARCH 2026 528 TABLE 894 LABORATORY CORPORATION OF AMERICA HOLDINGS: DEALS, JANUARY 2023–MARCH 2026 528 TABLE 895 LABORATORY CORPORATION OF AMERICA HOLDINGS: EXPANSIONS, JANUARY 2023–MARCH 2026 529 TABLE 896 LABORATORY CORPORATION OF AMERICA HOLDINGS: OTHER DEVELOPMENTS, JANUARY 2023–MARCH 2026 530 TABLE 897 FORTREA, INC.: BUSINESS OVERVIEW 531 TABLE 898 FORTREA, INC.: SERVICES/SOLUTIONS OFFERED 532 TABLE 899 FORTREA, INC.: SERVICE LAUNCHES, JANUARY 2023–MARCH 2026 534 TABLE 900 FORTREA, INC.: DEALS, JANUARY 2023–MARCH 2026 535 TABLE 901 FORTREA, INC.: EXPANSIONS, JANUARY 2023–MARCH 2026 536 TABLE 902 FORTREA, INC.: OTHER DEVELOPMENTS, JANUARY 2023–MARCH 2026 536 TABLE 903 SYNEOS HEALTH: COMPANY OVERVIEW 537 TABLE 904 SYNEOS HEALTH: SERVICES/SOLUTIONS OFFERED 537 TABLE 905 SYNEOS HEALTH: SERVICE LAUNCHES, JANUARY 2023–MARCH 2026 539 TABLE 906 SYNEOS HEALTH: DEALS, JANUARY 2023–MARCH 2026 539 TABLE 907 WUXI APPTEC: COMPANY OVERVIEW 541 TABLE 908 WUXI APPTEC: SERVICES/SOLUTIONS OFFERED 542 TABLE 909 WUXI APPTEC: EXPANSIONS, JANUARY 2023–MARCH 2026 544 TABLE 910 WUXI APPTEC: OTHER DEVELOPMENTS, JANUARY 2023–MARCH 2026 545 TABLE 911 CHARLES RIVER LABORATORIES: COMPANY OVERVIEW 546 TABLE 912 CHARLES RIVER LABORATORIES: SERVICES/SOLUTIONS OFFERED 547 TABLE 913 CHARLES RIVER LABORATORIES: DEALS, JANUARY 2023–MARCH 2026 548 TABLE 914 PAREXEL INTERNATIONAL CORPORATION: COMPANY OVERVIEW 550 TABLE 915 PAREXEL INTERNATIONAL CORPORATION: SERVICES/SOLUTIONS OFFERED 551 TABLE 916 PAREXEL INTERNATIONAL CORPORATION: DEALS, JANUARY 2023–MARCH 2026 552 TABLE 917 PAREXEL INTERNATIONAL CORPORATION: EXPANSIONS, JANUARY 2023–MARCH 2026 553 TABLE 918 PHARMARON: COMPANY OVERVIEW 554 TABLE 919 PHARMARON: SERVICES/SOLUTIONS OFFERED 555 TABLE 920 MEDPACE: COMPANY OVERVIEW 557 TABLE 921 MEDPACE: SERVICES/SOLUTIONS OFFERED 558 TABLE 922 SGS SA: COMPANY OVERVIEW 560 TABLE 923 SGS SA: SERVICES/SOLUTIONS OFFERED 561 TABLE 924 SGS SA: DEALS, JANUARY 2023–MARCH 2026 563 TABLE 925 FRONTAGE LABS: COMPANY OVERVIEW 564 TABLE 926 FRONTAGE LABS: SERVICES/SOLUTIONS OFFERED 565 TABLE 927 FRONTAGE LABS: DEALS, JANUARY 2023–MARCH 2026 567 TABLE 928 FRONTAGE LABS: OTHER DEVELOPMENTS, JANUARY 2023–MARCH 2026 568 TABLE 929 EUROFINS SCIENTIFIC: COMPANY OVERVIEW 569 TABLE 930 EUROFINS SCIENTIFIC: SERVICES/SOLUTIONS OFFERED 570 TABLE 931 TIGERMED: COMPANY OVERVIEW 572 TABLE 932 TIGERMED: SERVICES OFFERED 573 TABLE 933 TIGERMED: PRODUCT/ SERVICE APPROVALS, JANUARY 2023–MARCH 2026 575 TABLE 934 TIGERMED: DEALS, JANUARY 2023–MARCH 2026 575 TABLE 935 PSI CRO AG: COMPANY OVERVIEW 577 TABLE 936 PSI CRO AG: SERVICES/SOLUTIONS OFFERED 577 TABLE 937 PSI CRO AG: SERVICE LAUNCHES, JANUARY 2023–MARCH 2026 578 TABLE 938 PSI CRO AG: DEALS, JANUARY 2023–MARCH 2026 578 TABLE 939 PSI CRO AG: EXPANSIONS, JANUARY 2023–MARCH 2026 579 TABLE 940 BIOAGILE: COMPANY OVERVIEW 580 TABLE 941 BIOAGILE: SERVICES/SOLUTIONS OFFERED 580 TABLE 942 FIRMA CLINICAL RESEARCH: COMPANY OVERVIEW 582 TABLE 943 FIRMA CLINICAL RESEARCH: SERVICES/SOLUTIONS OFFERED 582 TABLE 944 ACCULAB LIFE SCIENCES: COMPANY OVERVIEW 583 TABLE 945 ACCULAB LIFE SCIENCES: SERVICES/SOLUTIONS OFFERED 583 TABLE 946 NOVOTECH: COMPANY OVERVIEW 584 TABLE 947 NOVOTECH: SERVICES/SOLUTIONS OFFERED 584 TABLE 948 NOVOTECH HEALTH HOLDINGS: DEALS, JANUARY 2023–MARCH 2026 586 TABLE 949 LINICAL: COMPANY OVERVIEW 588 TABLE 950 LINICAL: SERVICES/SOLUTIONS OFFERED 588 TABLE 951 LINICAL: EXPANSIONS, JANUARY 2023–MARCH 2026 589 TABLE 952 ADVANCED CLINICAL: COMPANY OVERVIEW 590 TABLE 953 ADVANCED CLINICAL: SERVICES/SOLUTIONS OFFERED 590 TABLE 954 ADVANCED CLINICAL: DEALS, JANUARY 2023–MARCH 2026 591 TABLE 955 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS 607 TABLE 956 CRO SERVICES MARKET: RISK ANALYSIS 610 FIGURE 1 MARKET SCENARIO 63 FIGURE 2 GLOBAL CRO SERVICES MARKET, 2024–2031 64 FIGURE 3 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN CRO SERVICES MARKET, 2023–2026 64 FIGURE 4 DISRUPTIONS INFLUENCING THE GROWTH OF THE CRO SERVICES MARKET 65 FIGURE 5 HIGH-GROWTH SEGMENTS IN CRO SERVICES MARKET, 2026–2031 66 FIGURE 6 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN THE CRO SERVICES MARKET, IN TERMS OF VALUE, DURING THE FORECAST PERIOD 67 FIGURE 7 INCREASING SIZE OF THE CLINICAL DEVELOPMENT PIPELINE TO PROPEL MARKET GROWTH 69 FIGURE 8 US AND SMALL MOLECULES SEGMENT COMMANDED LARGEST MARKET SHARES IN 2025 70 FIGURE 9 CHINA TO REGISTER HIGHER CAGR DURING FORECAST PERIOD 71 FIGURE 10 DRIVERS, OPPORTUNITIES, AND CHALLENGES: CRO SERVICES MARKET 72 FIGURE 11 ACTIVE PHARMACEUTICAL PIPELINE, 2015–2026 76 FIGURE 12 PORTER’S FIVE FORCES ANALYSIS: CRO SERVICES MARKET 83 FIGURE 13 CRO SERVICES MARKET: VALUE CHAIN ANALYSIS 86 FIGURE 14 CRO SERVICES MARKET: ECOSYSTEM ANALYSIS 88 FIGURE 15 INDICATIVE PRICING ANALYSIS (PER STUDY), BY REGION, 2025 (USD MILLION) 91 FIGURE 16 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESS IN CRO SERVICES MARKET 92 FIGURE 17 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CRO SERVICES, BY MODALITY 115 FIGURE 18 KEY BUYING CRITERIA FOR CRO SERVICES ACROSS END USERS 116 FIGURE 19 DRUGS IN PIPELINE, BY DEVELOPMENT PHASE, 2024 VS. 2025 122 FIGURE 20 CANCER (%) AS A PROPORTION OF PIPELINE IN DEVELOPMENT, 2013–2024 243 FIGURE 21 ESTIMATED NUMBER OF INDIVIDUALS WITH DIABETES, 2000–2045 (MILLION) 273 FIGURE 22 ANNUAL DRUG APPROVALS BY FDA CENTER FOR DRUG EVALUATION AND RESEARCH, 2013–2025 305 FIGURE 23 R&D SPENDING OF PHRMA MEMBER COMPANIES, 2013–2024 305 FIGURE 24 US FDA DE NOVO MEDICAL DEVICE APPROVALS, 2012–2024 315 FIGURE 25 NORTH AMERICA: CRO SERVICES MARKET SNAPSHOT 324 FIGURE 26 GLOBAL DISTRIBUTION OF R&D COMPANIES, JANUARY 2025 VS. JANUARY 2026 331 FIGURE 27 ASIA PACIFIC: CRO SERVICES MARKET SNAPSHOT 383 FIGURE 28 REVENUE ANALYSIS OF KEY PLAYERS IN CRO SERVICES MARKET (2021–2025) 489 FIGURE 29 MARKET SHARE ANALYSIS OF KEY PLAYERS IN CRO SERVICES MARKET (2025) 490 FIGURE 30 CRO SERVICES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 493 FIGURE 31 CRO SERVICES MARKET: COMPANY FOOTPRINT 494 FIGURE 32 CRO SERVICES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 498 FIGURE 33 EV/EBITDA OF KEY VENDORS 501 FIGURE 34 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 501 FIGURE 35 CRO SERVICES MARKET: SERVICE COMPARATIVE ANALYSIS 502 FIGURE 36 IQVIA INC.: COMPANY SNAPSHOT (2025) 507 FIGURE 37 ICON PLC: COMPANY SNAPSHOT (2024) 514 FIGURE 38 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT 519 FIGURE 39 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT (2025) 526 FIGURE 40 FORTREA, INC.: COMPANY SNAPSHOT 531 FIGURE 41 WUXI APPTEC: COMPANY SNAPSHOT 542 FIGURE 42 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT 547 FIGURE 43 PHARMARON: COMPANY SNAPSHOT 555 FIGURE 44 MEDPACE: COMPANY SNAPSHOT 558 FIGURE 45 SGS SA: COMPANY SNAPSHOT 561 FIGURE 46 FRONTAGE LABS: COMPANY SNAPSHOT 565 FIGURE 47 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT 570 FIGURE 48 TIGERMED: COMPANY SNAPSHOT 573 FIGURE 49 CRO SERVICES MARKET: RESEARCH DESIGN 598 FIGURE 50 CRO SERVICES MARKET: BREAKDOWN OF PRIMARIES (DEMAND- AND SUPPLY-SIDE PARTICIPANTS) 600 FIGURE 51 GLOBAL CRO SERVICES MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2025 601 FIGURE 52 GLOBAL CRO SERVICES MARKET SIZE ESTIMATION: COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH), 2025 602 FIGURE 53 ILLUSTRATIVE EXAMPLE OF IQVIA INC.: REVENUE SHARE ANALYSIS, 2025 603 FIGURE 54 CRO SERVICES MARKET SIZE VALIDATION FROM PRIMARY SOURCES 604 FIGURE 55 TOP-DOWN APPROACH 604 FIGURE 56 GLOBAL CRO SERVICES MARKET: CAGR PROJECTIONS, 2026–2031 606 FIGURE 57 CRO SERVICES MARKET: DATA TRIANGULATION METHODOLOGY 608